<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Prevention of venous thromboembolism in adults undergoing hip fracture repair or hip or knee replacement</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Prevention of venous thromboembolism in adults undergoing hip fracture repair or hip or knee replacement</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Prevention of venous thromboembolism in adults undergoing hip fracture repair or hip or knee replacement</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">James D Douketis, MD, FRCPC, FACP, FCCP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Siraj Mithoowani, MD, MHPE, FRCPC</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jess Mandel, MD, MACP, ATSF, FRCP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David A Garcia, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Geraldine Finlay, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Collins, MD, PhD, FACS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 25, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H828165"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>In adults undergoing major orthopedic procedures of the lower extremity, the risk of postoperative venous thromboembolism (VTE; lower extremity deep venous thrombosis, pulmonary embolism) is among the highest of all surgical procedures. Major orthopedic surgeries are considered the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Hip replacement surgery (eg, total or partial hip arthroplasty)</p><p class="bulletIndent1"><span class="glyph">●</span>Knee replacement surgery (eg, total or partial knee arthroplasty)</p><p class="bulletIndent1"><span class="glyph">●</span>Hip fracture surgery (including open reduction, internal fixation)</p><p></p><p>Our approach to management of adults undergoing major orthopedic surgery, all of whom are at <strong>high risk</strong> for VTE, is reviewed in this topic and is for the most part consistent with the American College of Chest Physicians and the American Society of Hematology recommendations [<a href="#rid1">1-5</a>].</p><p>VTE prevention in the following patient populations is <strong>not</strong> covered in this topic but is discussed elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>VTE prevention in adults undergoing orthopedic surgery who are at <strong>low risk</strong> for VTE – (See  <a class="medical medical_review" href="/z/d/html/128931.html" rel="external">"Prevention of venous thromboembolism (VTE) in adults undergoing non-major extremity orthopedic surgery"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nonorthopedic surgical patients – (See  <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">"Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pelvic ring fracture/hip fractures related to severe trauma – (See  <a class="medical medical_review" href="/z/d/html/15151.html" rel="external">"Severe pelvic fracture in the adult trauma patient"</a> and  <a class="medical medical_review" href="/z/d/html/113028.html" rel="external">"Venous thromboembolism risk and prevention in the severely injured trauma patient"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Multiple lower extremity fractures from severe trauma – (See  <a class="medical medical_review" href="/z/d/html/15150.html" rel="external">"Severe lower extremity injury in the adult patient"</a> and  <a class="medical medical_review" href="/z/d/html/113028.html" rel="external">"Venous thromboembolism risk and prevention in the severely injured trauma patient"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hospitalized medical patients – (See  <a class="medical medical_review" href="/z/d/html/1346.html" rel="external">"Prevention of venous thromboembolic disease in acutely ill hospitalized medical adults"</a>.)</p><p></p><p class="headingAnchor" id="H8"><span class="h1">RISK ASSESSMENT</span><span class="headingEndMark"> — </span>In patients undergoing major orthopedic surgery including total or partial hip arthroplasty, total or partial knee arthroplasty, and hip fracture surgery (eg, open reduction, internal fixation), we assess the risk of postoperative VTE, as well as postoperative bleeding, to select the optimal method of thromboprophylaxis. Indications for these surgeries are described separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4813.html" rel="external">"Hip fracture in older adults: Epidemiology and medical management"</a> and  <a class="medical medical_review" href="/z/d/html/7972.html" rel="external">"Total hip arthroplasty"</a> and  <a class="medical medical_review" href="/z/d/html/7973.html" rel="external">"Complications of total hip arthroplasty", section on 'Venous thromboembolism'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7967.html" rel="external">"Total knee arthroplasty"</a> and  <a class="medical medical_review" href="/z/d/html/7971.html" rel="external">"Complications of total knee arthroplasty", section on 'Thromboembolism'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4813.html" rel="external">"Hip fracture in older adults: Epidemiology and medical management"</a>.)</p><p></p><p class="headingAnchor" id="H1694874449"><span class="h2">Risk of thrombosis</span><span class="headingEndMark"> — </span>Major orthopedic procedures carry a <strong>high</strong> baseline risk for symptomatic VTE (approximately 4 to 5 percent), which can be increased further by the presence of additional procedure- and patient-related factors. Among all surgical patients, those undergoing major lower extremity orthopedic surgery are considered to have the highest baseline VTE risk. We do not use the Caprini score to assess VTE risk, since the score was validated in patients undergoing nonorthopedic surgery, and by default, all patients undergoing major orthopedic surgery are designated as high thrombotic risk [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">"Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients", section on 'Thrombosis risk model (Caprini)'</a>.)</p><p>In the past, baseline rates of VTE in patients undergoing major orthopedic surgery who were not receiving thromboprophylaxis were reported to be as high as 30 percent; however, data since then have reported rates less than 5 percent [<a href="#rid1">1,4,5,7,8</a>]. The American College of Chest Physicians (ACCP) has estimated the baseline perioperative, 35-day risk at 4.3 percent, with the highest risk occurring in the first 7 to 14 days (1.8 percent for symptomatic deep venous thrombosis [DVT] and 1 percent for pulmonary embolism [PE]) and lower rates in the subsequent 15 to 35 days (1 percent for symptomatic DVT and 0.5 percent for PE) [<a href="#rid1">1</a>].</p><p>Additional procedure- and patient-related risk factors that can further augment the risk of VTE in this population include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Procedure-related factors:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Greater extent and longer duration of surgery</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>General anesthesia (as opposed to spinal anesthesia)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Prolonged period of immobilization and/or casting postoperatively</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Bilateral total joint arthroplasty (as opposed to unilateral arthroplasty)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patient-related factors (see  <a class="medical medical_review" href="/z/d/html/1361.html" rel="external">"Overview of the causes of venous thrombosis"</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>General patient-related factors that can contribute to VTE risk in all surgical patients are listed in the table  (<a class="graphic graphic_table graphicRef59759" href="/z/d/graphic/59759.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patient-related factors that are specific to those undergoing major orthopedic surgery include age &gt;75 years (particularly ≥85 years), poor ambulation (prior to surgery), obesity, and cardiovascular disease [<a href="#rid9">9-13</a>].</p><p></p><p>Pathogenetic factors that may contribute to the particularly high risk in this group include compression of the deep veins from positioning of the extremity during hip surgery (eg, flexion and adduction of the hip) and possibly the use of a thigh tourniquet during knee surgery [<a href="#rid9">9,14-16</a>]. (See  <a class="medical medical_review" href="/z/d/html/7967.html" rel="external">"Total knee arthroplasty", section on 'Tourniquet use'</a>.)</p><p class="headingAnchor" id="H1723563727"><span class="h2">Risk of bleeding</span><span class="headingEndMark"> — </span>In estimating the risk of bleeding, the clinician should consider surgical- and patient-related factors:</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Factors attributable to surgery</strong> – Most experts consider patients undergoing major orthopedic surgery to have a <strong>high</strong> baseline risk of bleeding (2 to 4 percent)  (<a class="graphic graphic_table graphicRef86929" href="/z/d/graphic/86929.html" rel="external">table 2</a>). Although the risk of bleeding is high relative to other surgical procedures, in most cases, the risk is not so high as to preclude use of pharmacologic thromboprophylaxis unless the patient has a contraindication.</p><p></p><p class="bulletIndent1">Estimates of the baseline risk of bleeding in the absence of thromboprophylaxis in orthopedic patients have been hampered by factors, including derivation of data from heterogeneous populations, increasing use of thromboprophylaxis, improved surgical techniques, and use of adjunctive agents to limit bleeding (eg, <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">tranexamic acid</a>) (see  <a class="medical medical_review" href="/z/d/html/7972.html" rel="external">"Total hip arthroplasty", section on 'Minimizing blood loss'</a> and  <a class="medical medical_review" href="/z/d/html/7967.html" rel="external">"Total knee arthroplasty", section on 'Minimizing perioperative blood loss'</a>). Nonetheless, the ACCP and others have estimated that the average untreated bleeding risk in nontrauma patients is &lt;2 percent [<a href="#rid1">1,3-5,17</a>], suggesting that the influence of postoperative pharmacologic thromboprophylaxis has minimal effect on the risk of bleeding. However, rates are likely underestimated by the inclusion in trials of only those patients with a low risk of bleeding, such that the true rate is likely higher than 2 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional patient-related risk factors</strong> – Since there are no tools available to assess the risk of bleeding in this population, we obtain a full history and examination to assess the risk of major bleeding. Major bleeding is typically defined as fatal bleeding, symptomatic bleeding in a critical area or organ, bleeding causing a fall in hemoglobin of ≥2 g/dL or leading to transfusion of two or more units of whole blood or red cells, and/or bleeding requiring reoperation [<a href="#rid18">18</a>]. (See  <a class="medical medical_review" href="/z/d/html/113028.html" rel="external">"Venous thromboembolism risk and prevention in the severely injured trauma patient"</a>.)</p><p></p><p class="bulletIndent1">The risk of major bleeding is generally considered unacceptably high if any of the following are present  (<a class="graphic graphic_table graphicRef107527" href="/z/d/graphic/107527.html" rel="external">table 3</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Active, clinically significant bleeding (epistaxis and menstrual bleeding are <strong>not</strong> contraindications to pharmacologic thromboprophylaxis).</p><p class="bulletIndent2"><span class="glyph">•</span>Intracranial hemorrhage.</p><p class="bulletIndent2"><span class="glyph">•</span>Severe coagulopathy or bleeding diatheses.</p><p class="bulletIndent2"><span class="glyph">•</span>Platelet count &lt;50,000/microL.</p><p class="bulletIndent2"><span class="glyph">•</span>A condition in which bleeding is potentially catastrophic (eg, bleeding into a major organ, eye, or pericardial space).</p><p class="bulletIndent2"><span class="glyph">•</span>Anticipated or recent neuraxial anesthesia. The timing of neuraxial anesthesia relative to use of anticoagulation or antiplatelet medication is presented separately. (See  <a class="medical medical_review" href="/z/d/html/14930.html" rel="external">"Neuraxial anesthesia/analgesia techniques in the patient receiving anticoagulant or antiplatelet medication"</a>.)</p><p></p><p class="bulletIndent1">Elective or semielective surgery in patients with conditions that contraindicate anticoagulation can be delayed until the condition is under control (eg, control hypertension, improve platelet function, treat coagulopathy). For those surgeries that must proceed, patients are managed with mechanical prophylaxis alone until the risk of bleeding becomes acceptably low. (See <a class="local">'Patients with unacceptably high bleeding risk'</a> below.)</p><p></p><p class="headingAnchor" id="H480052627"><span class="h1">APPROACH TO PHARMACOLOGIC THROMBOPROPHYLAXIS (LOW-RISK BLEEDING)</span><span class="headingEndMark"> — </span>For patients undergoing major lower extremity orthopedic surgery (eg, hip fracture surgery, total or partial hip arthroplasty, total or partial knee arthroplasty) who are at low risk of bleeding, we recommend pharmacologic thromboprophylaxis with or without intermittent pneumatic compression (IPC) devices rather than no thromboprophylaxis. Patients who have contraindications to pharmacologic thromboprophylaxis  (<a class="graphic graphic_table graphicRef107527" href="/z/d/graphic/107527.html" rel="external">table 3</a>) should receive mechanical prophylaxis alone until the contraindication resolves. Risk of bleeding and mechanical prophylaxis are discussed separately. (See <a class="local">'Risk of bleeding'</a> above and <a class="local">'Patients with unacceptably high bleeding risk'</a> below.)</p><p>The clinician should be aware that any form of thromboprophylaxis <strong>reduces</strong> but does <strong>not eliminate</strong> the risk of VTE entirely. In addition, thromboprophylaxis has a greater impact on reducing the rate of asymptomatic rather than symptomatic events and has minimal effect on mortality. This is particularly true in patients with the highest risk of VTE (eg, patient undergoing total hip arthroplasty who has active cancer).</p><p class="headingAnchor" id="H309535186"><span class="h2">Choosing an agent</span><span class="headingEndMark"> — </span>Our general approach to choosing an agent for pharmacologic thromboprophylaxis in patients undergoing major lower extremity orthopedic procedures who are at low risk of bleeding is influenced by the type of surgery and comorbidities  (<a class="graphic graphic_algorithm graphicRef140146" href="/z/d/graphic/140146.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>First-line agents for patients undergoing total hip or total knee arthroplasty</strong> – For most patients undergoing hip or knee arthroplasty, we suggest low molecular weight (LMW) heparin or a direct oral anticoagulant (DOAC) as the initial agent in the early perioperative period (ie, up to 14 days). <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">Enoxaparin</a> or <a class="drug drug_general" data-topicid="9319" href="/z/d/drug information/9319.html" rel="external">dalteparin</a> are LMW heparin agents that are well studied and commonly used. Among the DOACs, we prefer <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a> or <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">apixaban</a> rather than <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">dabigatran</a> or <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">edoxaban</a> since there are more data to support their use in this setting. Dosing and efficacy of these agents are discussed below. (See <a class="local">'Low molecular weight heparin'</a> below and <a class="local">'Direct oral anticoagulants'</a> below.)</p><p></p><p class="bulletIndent1">We do <strong>not</strong> use <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> as the <strong>sole</strong> <strong>initial</strong> agent for thromboprophylaxis in the early postoperative period. This recommendation is in contrast with the practice of many orthopedic surgeons who commonly use aspirin as the sole agent for VTE prophylaxis, viewing it as an effective and safe agent. However, the typical dosing used by surgeons varies in practice and, in our opinion, the use of aspirin as a sole agent needs to be better supported with large, well-conducted, randomized trial data before we feel this approach should be routinely used. In <strong>select</strong> patients who are considered at lower risk for VTE (ie, do not have additional VTE risk factors), we do support switching to aspirin after a short course of anticoagulant therapy (eg, 5 to 10 days of <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a> or LMW heparin followed by aspirin for the remaining duration of thromboprophylaxis), which is discussed below. (See <a class="local">'Duration'</a> below and <a class="local">'Aspirin'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>First-line agent for patients undergoing hip fracture surgery</strong> – For most patients undergoing hip fracture surgery, we suggest LMW heparin as the preferred agent for the entire duration of prophylaxis (ie, up to 35 days). We generally avoid DOACs in this setting since their safety and efficacy have not been studied in this population. Limited observational data suggest that <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> may be an appropriate alternative. (See <a class="local">'Duration'</a> below and <a class="local">'Low molecular weight heparin'</a> below and <a class="local">'Aspirin'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with renal failure</strong> – In patients with severe renal failure (eg, creatinine clearance &lt;30 mL/min or on hemodialysis), <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">unfractionated heparin</a> (UFH) is the preferred agent; however, <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> may be used if heparin injections are undesirable (target international normalized ratio 2 to 3). Patients with less severe renal insufficiency can receive dose-adjusted LMW heparin  (<a class="graphic graphic_table graphicRef90258" href="/z/d/graphic/90258.html" rel="external">table 4</a>). (See <a class="local">'Unfractionated heparin'</a> below and <a class="local">'Warfarin'</a> below and <a class="local">'Low molecular weight heparin'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with heparin-induced thrombocytopenia (HIT)</strong> – Patients with HIT or history of HIT should be treated with a nonheparin agent, the details of which are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1369.html" rel="external">"Management of heparin-induced thrombocytopenia"</a>.)</p><p></p><p class="headingAnchor" id="H4276645185"><span class="h2">Timing of initiation</span><span class="headingEndMark"> — </span>The optimal timing of pharmacologic thromboprophylaxis in patients undergoing major orthopedic surgery is unknown. Practice is variable, depending on surgeon preference and the agent chosen.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>LMW heparin, UFH</strong> – Most experts agree that thromboprophylaxis with LMW heparin should <strong>not</strong> be administered close to surgery (eg, within four hours preoperatively and within four hours postoperatively). We prefer to start LMW heparin preoperatively with an initial dose ≥12 hours before surgery and then continue it postoperatively with a second dose ≥12 hours after surgery. Alternatively, LMW heparin can be started postoperatively with the first dose ≥12 hours after surgery, which is an option often preferred by orthopedic surgeons. We use the same approach when using low-dose UFH.</p><p></p><p class="bulletIndent1">This strategy is based upon trials that have suggested an unacceptably high bleeding risk when LMW heparin is given perioperatively (eg, within four hours of surgery) [<a href="#rid19">19,20</a>]. As an example, one randomized trial of patients undergoing total hip arthroplasty compared perioperative LMW heparin (<a class="drug drug_general" data-topicid="9319" href="/z/d/drug information/9319.html" rel="external">dalteparin</a> [started two hours before surgery], early postoperative LMW heparin [started four to six hours after surgery]), and postoperative <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> (started in the evening on the day of surgery). Although rates of symptomatic VTE were lower in the perioperative and early postoperative LMW heparin groups compared with postoperative warfarin (1.5 and 3 versus 4.4 percent, respectively), rates of major bleeding were higher (9 and 7 versus 4 percent, respectively) [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral agents</strong> – Oral agents such as DOACs and <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> are generally started postoperatively 6 to 12 hours or more after surgery, provided that the patient can eat. However, if oral intake is expected to be delayed, then LMW heparin (or UFH) should be administered subcutaneously in the interim. Many patients also receive LMW heparin ≥12 hours before surgery, although the value of this practice is unknown.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">Fondaparinux</a> – Fondaparinux is approved to start six or more hours <strong>after</strong> skin closure, consistent with major trials that demonstrated its efficacy. However, many experts administer the first dose 8 to 12 hours postoperatively to mitigate the bleeding risk, a practice that is also consistent with guidelines [<a href="#rid1">1-5</a>].</p><p></p><p class="headingAnchor" id="H2458513734"><span class="h2">Duration</span><span class="headingEndMark"> — </span>For most patients undergoing major lower extremity orthopedic surgery, we suggest that the initial thromboprophylaxis agent be continued for a <strong>minimum</strong> of 10 to 14 days  (<a class="graphic graphic_algorithm graphicRef140147" href="/z/d/graphic/140147.html" rel="external">algorithm 2</a>). Longer or shorter durations may be appropriate depending on the surgery and other risk factors:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hip arthroplasty</strong> – For patients undergoing hip arthroplasty, we suggest extending thromboprophylaxis for a total of 35 days. For most patients, the same agent is used for the entire 35-day course (typically LMW heparin or a DOAC). However, for select lower-risk patients, we suggest transitioning to <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> after 5 to 10 days of initial therapy with LMW heparin or DOAC and completing the remainder of the 35-day course with aspirin alone. Lower-risk patients are considered as those who fill all of the following criteria: no other risk factors for VTE, no other indications for long-term anticoagulation, no lower limb or hip fracture in the previous three months, surgery is elective and unilateral, and the patient is ambulatory within 24 hours after surgery.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Knee arthroplasty</strong> – For most patients undergoing knee arthroplasty, we suggest <strong>not</strong> extending thromboprophylaxis beyond 14 days, provided that the patient is fully ambulatory and discharged to home by the end of this period. For lower-risk patients (as defined above), we suggest transitioning to <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> after five days of initial therapy with LMW heparin or DOAC and completing the remainder of the 10- to 14-day course with aspirin alone. For other patients, LMW heparin or DOAC prophylaxis is continued for the full 10- to 14-day course. In patients who are not yet ambulatory by 14 days, LMW heparin or DOAC prophylaxis is continued until fully ambulatory or 35 days, whichever is shorter.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hip fracture surgery</strong> – For patients undergoing hip fracture surgery, we suggest extending thromboprophylaxis for a total of 35 days. The same agent is used for the entire 35-day course (typically LMW heparin), although <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> is sometimes used in some patients as an alternative.</p><p></p><p>The practice of extending the duration of thromboprophylaxis beyond 10 to 14 days is supported by clinical trials and meta-analyses demonstrating that extended prophylaxis reduces the incidence of VTE without increasing the risk of major bleeding [<a href="#rid21">21-36</a>]. Most of these trials involved patients undergoing total hip arthroplasty. There are few data on patients undergoing hip fracture surgery, but it is reasonable to believe that extended prophylaxis would have similar benefits in this population. The benefits of extending thromboprophylaxis in patients undergoing total knee replacement are less certain. Two trials directly addressed this population and did not detect significant differences in rates of VTE with extended versus short-term thromboprophylaxis [<a href="#rid29">29,37</a>].</p><p>In a meta-analysis of six trials involving 2544 patients undergoing total hip (1795 patients) or knee arthroplasty (749 patients), extended thromboprophylaxis with LMW heparin for 28 to 42 days reduced the overall rate of VTE (3.7 versus 8.3 percent; relative risk [RR] 0.39, 95% CI 0.28-0.59) [<a href="#rid36">36</a>]. The rate of symptomatic VTE was also lower (2 versus 3.3 percent; RR 0.59, 95% CI 0.35-1.01), but the finding did not achieve statistical significance. There were more episodes of minor bleeding in the extended prophylaxis group, but rates of major bleeding were similarly low in both groups (0.2 versus 0.4 percent). Mortality was the same in both groups (0.4 percent).</p><p>Extended-duration thromboprophylaxis with DOACs appears to have similar benefit, though the available trials are limited to patients undergoing total hip arthroplasty [<a href="#rid21">21-23,38</a>]. In a trial involving 2509 patients undergoing total hip arthroplasty who were randomly assigned to extended thromboprophylaxis with a DOAC (<a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a>) for 31 to 39 days or short-term thromboprophylaxis with LMW heparin for 10 to 14 days, extended prophylaxis reduced both the overall rate of VTE (0.6 versus 5.1 percent) and the rate of symptomatic VTE (0.2 versus 1.2 percent) [<a href="#rid21">21</a>]. Mortality was low in both groups (0.2 versus 0.7 percent). There were more episodes of nonmajor bleeding in the extended prophylaxis group (6.5 versus 5.5 percent), but the rate of major bleeding was similarly low in both groups (one event in each).</p><p>The evidence supporting the practice of transitioning to <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> after five days of pharmacologic thromboprophylaxis in select lower-risk patients is discussed below. (See <a class="local">'Aspirin'</a> below.)</p><p>It is uncertain whether courses shorter than 10 to 14 days can be used in select patients (eg, fast-track, short-stay patients). In one observational study of &gt;17,000 patients undergoing fast-track total hip arthroplasty or total knee arthroplasty who had hospital length of stay &lt;5 days and received thromboprophylaxis only while in the hospital, the VTE rate was 0.4 percent [<a href="#rid39">39</a>]. However, the data are preliminary and we suggest <strong>not</strong> routinely using a shortened course of thromboprophylaxis unless these findings are confirmed in prospective clinical trials.</p><p class="headingAnchor" id="H332112709"><span class="h2">Role of combined pharmacologic and mechanical thromboprophylaxis</span><span class="headingEndMark"> — </span>While a combined strategy is unlikely to be harmful, there are no convincing data demonstrating a clear benefit. In addition, mechanical devices can be bothersome to many patients, particularly in the postoperative setting. Given the uncertainty of the additional benefit when added to pharmacologic prophylaxis, we generally do not insist upon their use. However, other centers may use them more routinely.</p><p class="bulletIndent1"><span class="glyph">●</span>In a post-hoc analysis of a randomized trial involving patients undergoing total knee arthroplasty that compared <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">edoxaban</a> and <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a>, there was a nonsignificant reduction in the incidence of VTE in patients who received concomitant anticoagulation and graduated compression stocking (GCS) compared with those who were anticoagulated without GCS (6 versus 13 percent) [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a small trial involving patients who underwent knee arthroplasty and were managed postoperatively with combined pharmacologic and mechanical prophylaxis, extending the use of mechanical prophylaxis to the outpatient setting reduced the rate of deep venous thrombosis (DVT) [<a href="#rid41">41</a>]. However, the events in this trial may not have been clinically significant, since most DVT were asymptomatic and all resolved within three months. In another trial involving patients undergoing total hip arthroplasty, six weeks of combined mechanical and pharmacologic prophylaxis (ie, IPC plus <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>) did not significantly reduce rates of VTE compared with aspirin alone [<a href="#rid42">42</a>].</p><p></p><p class="headingAnchor" id="H748158074"><span class="h1">SPECIFIC AGENTS</span><span class="headingEndMark"> — </span>Common agents that are used are discussed in this section. Investigational agents, such as milvexian (a factor XIa inhibitor), are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/138700.html" rel="external">"Investigational anticoagulants", section on 'Inhibitors of factor XI or factor XIa'</a>.)</p><p class="headingAnchor" id="H1356843796"><span class="h2">First-line options</span><span class="headingEndMark"> — </span>First-line options for anticoagulant VTE prophylaxis after total or partial hip arthroplasty, total or partial knee arthroplasty are LMW heparin, selected direct oral anticoagulants (DOACs; <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a>, <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">apixaban</a>), and <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> started after an initial five-day treatment with a DOAC (rivaroxaban) or LMW heparin.</p><p>First-line options for anticoagulant VTE prophylaxis after hip fracture surgery is LMW heparin.</p><p class="headingAnchor" id="H170693209"><span class="h3">Low molecular weight heparin</span><span class="headingEndMark"> — </span>Low molecular weight (LMW) heparin is a first-line agent for VTE prophylaxis in patients undergoing lower extremity major orthopedic surgery (eg, total or partial hip arthroplasty, total or partial knee arthroplasty, hip fracture surgery). Its efficacy is supported by multiple randomized trials that have demonstrated lower rates of symptomatic VTE and similar bleeding rates when compared with prophylactic-dose <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">unfractionated heparin</a> (UFH) or therapeutic anticoagulation with <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>. (See <a class="local">'Efficacy'</a> below.)</p><p>Additional details of agent choice, timing, and duration are discussed above. (See <a class="local">'Choosing an agent'</a> above and <a class="local">'Timing of initiation'</a> above and <a class="local">'Duration'</a> above.)</p><p class="headingAnchor" id="H3869006664"><span class="h4">Dosing</span><span class="headingEndMark"> — </span>Our suggested dosing regimens below differ somewhat from product label recommendations but are generally consistent with 2012 American College of Chest Physicians guidelines on antithrombotic therapy and prevention of thrombosis [<a href="#rid1">1,3-5</a>]. Additional dosing options, including alternatives found in the labeling, are provided separately in the drug information monographs included with UpToDate. LMW heparin agents are renally cleared to varying degrees, and dose adjustment is advised for patients with renal insufficiency  (<a class="graphic graphic_table graphicRef90258" href="/z/d/graphic/90258.html" rel="external">table 4</a>). LMW heparin is typically avoided in individuals with severe renal failure (eg, creatinine clearance &lt;30 mL/min or on dialysis). Dose adjustment is also necessary for patients who have obesity  (<a class="graphic graphic_table graphicRef65464" href="/z/d/graphic/65464.html" rel="external">table 5</a>).</p><p>Suggested dosing in patients without renal insufficiency who are not obese is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">Enoxaparin</a> – For patients undergoing hip or knee arthroplasty or hip fracture surgery [<a href="#rid43">43</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hip arthroplasty and hip fracture surgery: 30 mg subcutaneously every 12 hours <strong>or</strong> 40 mg once daily started either ≥12 hours before or ≥12 hours after surgery.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Knee arthroplasty: 30 mg subcutaneously every 12 hours started either ≥12 hours before or ≥12 hours after surgery. Some experts administer 40 mg once daily, either ≥12 hours before or ≥12 hours after surgery, although this dosing is based upon practice rather than data.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9319" href="/z/d/drug information/9319.html" rel="external">Dalteparin</a> – For patients undergoing total hip or total knee arthroplasty (off-label): 5000 units subcutaneously once daily started either ≥12 hours before or ≥12 hours after surgery [<a href="#rid3">3,44</a>]. If the initial dose is administered within four to eight hours of surgery (which is <strong>not</strong> our suggested approach), the United States product labeling recommends using one-half of the initial dose (2500 units) followed by the usual maintenance dose thereafter.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10009" href="/z/d/drug information/10009.html" rel="external">Tinzaparin</a> – For patients undergoing total hip or total knee arthroplasty: 4500 units subcutaneously once daily started either ≥12 hours before or ≥12 hours after surgery [<a href="#rid45">45,46</a>]. Tinzaparin is not available in the United States.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10060" href="/z/d/drug information/10060.html" rel="external">Nadroparin</a> – For patients undergoing total hip or total knee arthroplasty: 38 units/kg subcutaneously once daily (maximum: 3800 units) starting either ≥12 hours before or ≥12 hours after surgery; on postoperative day 4, increase the dose to 57 units/kg once daily (maximum: 5700 units) [<a href="#rid47">47</a>]. Nadroparin is not available in the United States.</p><p></p><p class="headingAnchor" id="H890156114"><span class="h4">Efficacy</span><span class="headingEndMark"> — </span>Clinical trials have evaluated the efficacy of LMW heparin compared with placebo, direct oral anticoagulants (DOACs), UFH, and <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>LMW heparin versus</strong> <strong>placebo</strong> – In randomized placebo-controlled trials performed in the 1980s to 1990s in patients undergoing total hip arthroplasty, total knee arthroplasty, and hip fracture surgery, LMW heparin consistently reduced the incidence of asymptomatic VTE by approximately 50 percent [<a href="#rid48">48-52</a>]. The effect on symptomatic events, pulmonary embolism (PE), and bleeding was inconsistently reported.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>LMW heparin versus DOACs</strong> – Data comparing LMW heparin and DOACs are discussed below. (See <a class="local">'Direct oral anticoagulants'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>LMW heparin versus</strong> <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> – There have been several randomized trials and meta-analyses comparing LMW heparin with therapeutic warfarin in patients undergoing total hip arthroplasty and total knee arthroplasty but <strong>not</strong> hip fracture surgery [<a href="#rid19">19,53-63</a>]. Most trials confirm that LMW heparin reduces the VTE rate by approximately one-third compared with warfarin. While earlier studies reported more major bleeding events associated with LMW heparin, later studies that compared these agents in the context of extended thromboprophylaxis did not find important differences in the risk of bleeding [<a href="#rid64">64</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>LMW heparin versus</strong> <strong>UFH</strong> – In patients undergoing major orthopedic surgery, several randomized trials and meta-analyses have reported that LMW heparin is more effective than prophylactic UFH (ie, 5000 units twice daily) and has similar bleeding rates [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1">In a meta-analysis of 64 trials of mixed medical and surgical patients (including &gt;3000 patients undergoing hip or knee arthroplasty or hip fracture surgery), LMW heparin reduced the rate of asymptomatic deep venous thrombosis (DVT) compared with prophylactic UFH (20 percent relative risk reduction) without an increase in the risk of major bleeding [<a href="#rid17">17</a>]. This effect was consistent among the subgroups of total hip arthroplasty, total knee arthroplasty, and hip fracture surgery.</p><p></p><p class="bulletIndent1">LMW heparin also appears to have similar efficacy compared with higher doses of UFH (eg, 7500 units every 12 hours) but with lower bleeding risk [<a href="#rid65">65</a>]. A comparison of LMW heparin and eight hourly regimen of low-dose UFH has not been adequately studied in orthopedic patients. However, one meta-analysis that included surgical patients, some of whom had orthopedic surgery, showed similar rates of VTE between 8 hourly and 12 hourly regimens of UFH [<a href="#rid66">66</a>]. (See  <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">"Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients", section on 'Low-dose unfractionated heparin'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>LMW heparin versus</strong> <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> – Many but not all studies testing the efficacy of aspirin for thromboprophylaxis after major orthopedic surgery suggest that it may be less effective than LMW heparin but may also be associated with lower bleeding rates, making it an attractive option in the surgical setting [<a href="#rid67">67-71</a>]. These data are discussed below. (See <a class="local">'Aspirin'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>LMW heparin versus </strong><a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> – Studies comparing LMW heparin and fondaparinux are discussed below. (See <a class="local">'Fondaparinux'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>LMW heparin versus mechanical thromboprophylaxis</strong> – LMW heparin has been poorly studied in comparison with mechanical methods (intermittent pneumatic compression [IPC], venous foot pump [VFP] devices, graduated compression stockings [GCS]) [<a href="#rid72">72-76</a>]. In one randomized trial involving 1761 patients undergoing total knee arthroplasty, LMW heparin reduced the composite endpoint of DVT or death compared with GCS alone (0.9 versus 3.2 percent) [<a href="#rid72">72</a>]. However, most of the events in the composite outcome were episodes of asymptomatic distal DVT.</p><p></p><p class="bulletIndent1">In another randomized trial of 274 patients undergoing total hip arthroplasty, there was a nonsignificant trend toward fewer proximal DVT in the LMW heparin group compared with those assigned to VFP alone (9 versus 13 percent) [<a href="#rid75">75</a>]. There were no major bleeding complications, but many patients (&gt;20 percent) were intolerant of the VFP.</p><p></p><p class="headingAnchor" id="H3219842661"><span class="h3">Direct oral anticoagulants</span><span class="headingEndMark"> — </span>Several DOACs that inhibit either factor Xa (<a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a>, <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">apixaban</a>, <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">edoxaban</a>) or thrombin (<a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">dabigatran</a>) are approved and are being increasingly used as an alternative to LMW heparin for VTE prophylaxis following major orthopedic surgery [<a href="#rid77">77,78</a>]. Together with LMW heparin, DOACs are a first-line agent for VTE prophylaxis in patients undergoing total hip or knee arthroplasty. We avoid their use in patients following hip fracture surgery because there are insufficient data in this population. On balance, evidence from meta-analyses of randomized trials involving patients undergoing total hip or knee arthroplasty suggests that DOACs have equivalent efficacy and safety when compared with LMW heparin. (See <a class="local">'Efficacy'</a> below.)</p><p></p><p>A key advantage of DOACs is that they avoid injections and monitoring associated with LMW heparin and <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>, respectively. In addition, they can be used in patients with a history of heparin-induced thrombocytopenia (HIT). DOACs should be avoided in patients with severe renal insufficiency (eg, creatinine clearance &lt;30 mL/min).</p><p>Additional details regarding agent choice, timing, and duration are discussed above. (See <a class="local">'Choosing an agent'</a> above and <a class="local">'Timing of initiation'</a> above and <a class="local">'Duration'</a> above.)</p><p class="headingAnchor" id="H3642817055"><span class="h4">Dosing</span><span class="headingEndMark"> — </span>Suggested dosing for individual DOACs are the following (see  <a class="medical medical_review" href="/z/d/html/1370.html" rel="external">"Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">Rivaroxaban</a> – 10 mg once daily started 6 to ≥10 hours after surgery</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">Apixaban</a> – 2.5 mg twice daily started ≥12 hours after surgery</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">Dabigatran</a> – 110 mg given one to four hours after surgery and 220 mg once daily thereafter</p><p></p><p>Dosing in patients with obesity is unclear. The International Society on Thrombosis and Haemostasis suggests that for patients with a body mass index &gt;40 kg/m<sup>2</sup> or weight &gt;120 kg, standard dosing for <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a> and <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">apixaban</a> rather than other DOACs can be used in this population [<a href="#rid79">79</a>].</p><p class="headingAnchor" id="H1043172513"><span class="h4">Efficacy</span><span class="headingEndMark"> — </span>In the available randomized trials evaluating the efficacy of DOACs, rates of symptomatic DVT have generally been similar to or lower than LMW heparin [<a href="#rid21">21-23,38,53,80-102</a>]. While most analyses report no difference in rates of bleeding, some studies report a possible modest increase in bleeding risk with DOACs compared with LMW heparin. On balance, we believe the data suggest that the safety and efficacy of DOACs for the prevention of VTE are similar to LMW heparin.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Meta-analyses of DOACs versus LMW heparin</strong> – In a meta-analysis of 22 randomized trials (32,159 patients) that compared the factor Xa inhibitors (eg, <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a>, <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">apixaban</a>, <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">edoxaban</a>) with LMW heparin for VTE prevention following hip or knee arthroplasty, there were fewer symptomatic DVTs in the DOAC group (4 fewer events per 1000) but at the expense of an increased risk of bleeding (2 more bleeding events per 1000) [<a href="#rid82">82</a>]. One limitation of these data is that follow-up was incomplete in some of the trials. In addition, most trials that compared DOACs with <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a> used the lower dose of enoxaparin (40 mg daily rather than 30 mg twice daily), which may have led to overestimation of the efficacy (and bleeding risk) of DOACs relative to LMW heparin.</p><p></p><p class="bulletIndent1">In a subsequent network meta-analysis, patients who received factor Xa inhibitors had a lower incidence of DVT compared with LMW heparin (odds ratio [OR] 0.45, 95% CI 0.35-0.57) without an apparent increase in the rate of bleeding (OR 1.21, 95% CI 0.79-1.90) [<a href="#rid53">53</a>].</p><p></p><p class="bulletIndent1">A meta-analysis evaluating the direct thrombin inhibitor <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">dabigatran</a>, compared with LMW heparin, did not detect significant differences in rates of symptomatic VTE (relative risk [RR] 0.71, 95% CI 0.23-2.12) or clinically important bleeding (RR 1.12, 95% CI 0.94-1.35) [<a href="#rid84">84</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Studies of individual DOACs versus LMW heparin</strong> – Data comparing the individual DOAC agents with LMW heparin include the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">Rivaroxaban</a> – Clinical trials involving patients undergoing total hip and total knee arthroplasty, but <strong>not</strong> hip fracture surgery, reported that rivaroxaban has similar or superior efficacy compared with LMW heparin [<a href="#rid21">21,38,87-92</a>]. Some trials showed a trend toward an increase in bleeding; however, this was not a consistent finding.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">Dabigatran</a> – The efficacy of dabigatran has been evaluated in randomized controlled trials involving patients undergoing total hip and total knee arthroplasty but <strong>not</strong> hip fracture surgery (including REMODEL, RENOVATE, REMOBILIZE) [<a href="#rid22">22,93-97</a>]. A meta-analysis of these trials reported similar efficacy and safety of dabigatran when compared with LMW heparin [<a href="#rid95">95</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">Apixaban</a> – Randomized trials involving patients undergoing total hip and total knee arthroplasty report comparable rates of VTE between apixaban and LMW heparin without an increased risk of bleeding [<a href="#rid23">23,103-105</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">Edoxaban</a> – Data regarding the use of edoxaban for the prevention of VTE come from two randomized trials in Japanese patients undergoing total hip arthroplasty or total knee arthroplasty (STARS E-3 and STARS J-5) [<a href="#rid98">98-100</a>]. In a pooled analysis of the two trials, edoxaban lowered the incidence of VTE compared with LMW heparin (5.1 versus 10.7 percent) with a similar safety profile [<a href="#rid106">106</a>]. Edoxaban has not yet received regulatory approval for prevention of VTE in most countries.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Studies comparing DOACs with one another</strong> – The different DOAC agents have not been directly compared with one another in head-to-head clinical trials. Studies comparing them indirectly using network meta-analysis methodology have reached variable conclusions [<a href="#rid85">85,86,107</a>]. In a network meta-analysis of data from six randomized trials that compared different DOACs with LMW heparin (<a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">apixaban</a> in one trial [5395 patients], <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">dabigatran</a> in two trials [7400 patients], <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">edoxaban</a> in one trial [8240 patients], and <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a> in two trials [8255 patients]), there were no important differences among the DOACs with regard to the risk of VTE [<a href="#rid107">107</a>]. The risk of major or clinically significant bleeding was lower with apixaban compared with rivaroxaban (RR 0.47, 95% CI 0.36-0.61), dabigatran (RR 0.69, 95% CI 0.51-0.94), and edoxaban (RR 0.54, 95% CI 0.41-0.69). Dabigatran was also associated with lower bleeding risk compared with rivaroxaban (RR 0.68, 95% CI 0.53-0.87) and edoxaban (RR 0.77, 95% CI 0.60-0.99).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Studies of extended-duration thromboprophylaxis</strong> – Limited data of DOACs in the extended-duration setting (eg, for 35 days) suggest similar efficacy to DOACs administered for 10 to 15 days. Studies evaluating shorter versus longer duration of thromboprophylaxis are discussed above. (See <a class="local">'Duration'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Studies comparing DOACs with agents other than LMW heparin</strong> – Studies comparing DOACs with other agents, such as <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> (for extended prophylaxis) and <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a>, are discussed below (see <a class="local">'Aspirin'</a> below and <a class="local">'Fondaparinux'</a> below). DOACs have not been directly compared with <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> or UFH.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Studies in patients with HIT</strong> – The use of DOACs in patients with a history of HIT is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1369.html" rel="external">"Management of heparin-induced thrombocytopenia", section on 'Direct oral anticoagulants'</a>.)</p><p></p><p class="headingAnchor" id="H2164200688"><span class="h3">Aspirin</span><span class="headingEndMark"> — </span>The use of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> for thromboprophylaxis in patients undergoing major orthopedic surgery is best supported for <strong>select</strong> lower-risk patients (see <a class="local">'Risk of thrombosis'</a> above) as an extended-duration prophylactic agent following an initial 5- to 10-day course of anticoagulant prophylaxis (eg, LMW heparin or DOAC) [<a href="#rid24">24,108</a>]. We do <strong>not</strong> typically use aspirin as a sole initial agent during the early postoperative course. Aspirin may also be an alternative to LMW heparin in select low-risk patients who undergo surgery for lower extremity trauma (eg, young males with pelvic or acetabular fracture) [<a href="#rid71">71,109</a>]. VTE prophylaxis in trauma patients is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/113028.html" rel="external">"Venous thromboembolism risk and prevention in the severely injured trauma patient"</a>.)</p><p>When <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> is used as an extended-duration prophylactic agent following an initial 5- to 10-day course of anticoagulant prophylaxis, our preferred dosing is 81 mg once daily [<a href="#rid24">24</a>]. When aspirin is used as the sole agent, we use 81 mg orally twice daily [<a href="#rid109">109,110</a>] or, less commonly, 160 mg once daily [<a href="#rid111">111</a>] since these doses were used in large randomized trials. Higher doses (eg, 325 mg twice daily) do not appear to be more effective than lower doses [<a href="#rid112">112,113</a>]. In the past, doses as high as 500 mg three times a day were used; however, adverse effects were unacceptably high with the higher dosing.</p><p>The efficacy of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> as a prophylactic agent is supported by randomized clinical trials [<a href="#rid24">24,70,110,111,114</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Studies on transitioning to </strong><a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a><strong> for extended prophylaxis in lower-risk patients</strong> – The largest trial evaluating the use of aspirin for extended thromboprophylaxis in patients undergoing major orthopedic surgery was the EPCAT II trial [<a href="#rid24">24</a>]. In this trial, 3424 patients who underwent total hip or total knee arthroplasty and who received initial thromboprophylaxis for five days with the DOAC <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a> were then randomized to aspirin (81 mg once daily) or rivaroxaban for ongoing thromboprophylaxis on subsequent days [<a href="#rid24">24</a>]. The duration of thromboprophylaxis depended on the surgery: Patients who underwent total knee arthroplasty received an additional nine days of therapy, and those who underwent total hip arthroplasty received an additional 30 days of therapy. Patients included in this trial were highly selected and included only those at the lower end of the spectrum of risk for VTE (ie, no other risk factors for VTE, no other indications for long-term anticoagulation, no lower limb or hip fracture in the previous three months, surgery was elective and unilateral, and patient was ambulatory within 24 hours after surgery). In this population, transitioning to aspirin after the initial five days resulted in similar rates of VTE (&lt;1 percent) and major bleeding (&lt;1 percent) compared with continued rivaroxaban. An earlier and smaller trial (EPCAT) in patients undergoing total hip arthroplasty reported similar findings [<a href="#rid110">110</a>]. Noteworthy is the dose of aspirin used is not typical of that used in practice. Whether higher doses could have achieved similar efficacy if aspirin was used alone was not studied.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Studies on </strong><a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a><strong> as the sole thromboprophylactic agent</strong> – Compared with no thromboprophylaxis, aspirin has been shown to reduce the incidence of symptomatic VTE in patients undergoing major orthopedic surgery, particularly <strong>hip fracture surgery</strong>, with a relative risk reduction of approximately 30 percent [<a href="#rid109">109,111</a>]. However, the efficacy of aspirin compared with anticoagulant thromboprophylaxis (LMW heparin, DOACs, <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>, or UFH) in this setting is less certain, with most trials reporting inferior or similar efficacy [<a href="#rid70">70,114</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a randomized crossover trial (CRISTAL) of 9711 patients, <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> (100 mg orally per day) was compared with <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a> (40 mg subcutaneously per day) for 35 days after hip arthroplasty and 14 days after knee arthroplasty [<a href="#rid71">71</a>]. Enoxaparin was superior to aspirin in preventing symptomatic VTE (above- or below-knee DVT and PE) at 90 days (1.82 versus 3.45 percent). There was no difference in the rates of major bleeding (&lt;0.5 percent) and death. The outcome was mostly driven by enoxaparin's superiority at preventing distal DVT (1.2 versus 2.4 percent) rather than proximal DVT (0.2 percent each) or PE (0.6 versus 1.1 percent). Interpretation is limited since the trial was stopped early for harm, hospitals were not blinded to treatment allocation, and 5 percent of patients were lost to follow-up.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In another trial of over 12,000 patients with polytrauma who underwent surgical treatment for fracture (METRC), the incidence of VTE was no different among patients who had <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> alone for 21 days compared with LMW heparin (DVT 2.51 percent [aspirin] versus 1.71 percent [LMW heparin]; PE 1.5 percent in each group) [<a href="#rid109">109</a>]. Also reported were similar rates of bleeding (14 percent each) and wound infections (&lt;1 percent each). However, noninferiority for aspirin in this trial may be limited to the population studied; this included a heterogeneous group of patients with polytrauma, which mostly comprised younger males (average age 45 years) and, therefore, may not apply to the typical patient population who undergoes THA or hip fracture surgery (ie, older females). This trial is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/113028.html" rel="external">"Venous thromboembolism risk and prevention in the severely injured trauma patient"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A meta-analysis of 13 randomized trials (6060 participants) compared <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> with various anticoagulants (LMW heparin, <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a>, <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>) in patients undergoing total hip or total knee arthroplasty [<a href="#rid114">114</a>]. No significant difference in VTE rate (RR 1.12, 95% CI 0.78-1.62) or rate of major bleeding (RR 1.11, 95% CI 0.47-2.59) was reported. However, there was considerable heterogeneity between studies, which limits the certainty of the findings. In addition, while the meta-analysis included the two trials discussed above where aspirin followed anticoagulation (EPCAT and EPCAT II [<a href="#rid24">24,110</a>]), it did not include the trials above where aspirin was the sole agent used for DVT prophylaxis [<a href="#rid71">71,109</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Retrospective studies have reached variable conclusions regarding the efficacy of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> in this setting [<a href="#rid115">115-118</a>], with some reporting similar VTE rates in patients treated with aspirin compared with other agents [<a href="#rid115">115</a>], while others reported lower VTE rates in patients receiving aspirin [<a href="#rid116">116,117</a>]. However, data from retrospective studies are fundamentally limited since they are highly susceptible to selection bias (ie, aspirin is more often used in lower-risk patients), and thus firm conclusions cannot be drawn from these studies.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In one older trial, <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> administered for 21 days was also found to be superior to <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> for the prevention of venographically detected DVT following hip fracture surgery (20 versus 41 percent) [<a href="#rid119">119</a>].</p><p></p><p class="headingAnchor" id="H3505999279"><span class="h2">Second-line options</span><span class="headingEndMark"> — </span>Second-line options include prophylactic-dose UFH, <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>, and <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a>. Use of these agents for VTE prophylaxis in the setting of major lower extremity orthopedic surgery is generally limited to patients in whom LMW heparin and DOACs cannot be administered (eg, patients with severe renal insufficiency, cost prohibitive).</p><p class="headingAnchor" id="H4249348948"><span class="h3">Unfractionated heparin</span><span class="headingEndMark"> — </span>UFH is a second-line option that can be used in patients who cannot receive LMW heparin or DOACs (eg, due to renal failure). Choosing an agent is described above. (See <a class="local">'Choosing an agent'</a> above.)</p><p>It is given at a dose of 5000 units subcutaneously twice daily (less commonly, three times daily). In patients with obesity, the optimal dose is unknown and some experts use 7500 units twice daily, but data to support this regimen are limited [<a href="#rid120">120,121</a>]. No renal adjustment is necessary.</p><p>The efficacy of UFH in this setting was studied in randomized trials carried out in the 1970s to 1990s. In a meta-analysis of eight trials involving &gt;500 patients undergoing hip arthroplasty, UFH reduced the incidence of DVT by 44 percent compared with no thromboprophylaxis (RR 0.53, 95% CI 0.32-0.89). Similar findings were noted in trials involving patients undergoing hip fracture surgery (RR 0.56, 95% CI 0.39-0.81; six trials) [<a href="#rid1">1,17</a>].</p><p>Trials demonstrating the inferiority of UFH compared with LMW heparin are described above. (See <a class="local">'Low molecular weight heparin'</a> above.)</p><p class="headingAnchor" id="H2340878165"><span class="h3">Warfarin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">Warfarin</a> is a second-line agent for VTE prophylaxis following major orthopedic surgery. Its use is mostly limited to patients who cannot take DOACs or LMW heparin (eg, patients with severe renal insufficiency). Choosing an agent is described above. (See <a class="local">'Choosing an agent'</a> above.)</p><p>Typical dosing regimens for <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> start at 5 mg orally once daily; occasionally, a lower or higher starting dose is warranted. Warfarin is started 12 to 24 hours after surgery (provided that the patient can eat) or the evening before surgery. While some experts adjust thereafter for a therapeutic target international normalized ratio (INR) of 1.5 to 2.5 [<a href="#rid122">122-124</a>], most experts adjust to target an INR of 2.5 (range 2 to 3). We use a validated warfarin dose adjustment nomogram since genotype-guided warfarin dosing does not offer any advantage over standard dosing regimens. (See  <a class="medical medical_review" href="/z/d/html/1334.html" rel="external">"Warfarin and other VKAs: Dosing and adverse effects"</a>.)</p><p>Compared with no thromboprophylaxis, therapeutic anticoagulation with <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> has been shown in older trials to reduce the incidence of asymptomatic VTE in patients undergoing major hip surgery, particularly hip fracture surgery, with a relative risk reduction of 55 percent [<a href="#rid17">17,119,125</a>]. In one trial, warfarin was also found to be superior to <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> for the prevention of DVT following hip fracture surgery [<a href="#rid119">119</a>]. In addition, warfarin has been shown to be more effective than mechanical methods of thromboprophylaxis (eg, IPC devices) in most trials [<a href="#rid126">126-129</a>]. However, more recent clinical trials and meta-analyses report inferiority of warfarin compared with LMW heparin, as discussed above. (See <a class="local">'Low molecular weight heparin'</a> above.)</p><p>Whether low-intensity regimens are of similar efficacy to standard-intensity regimens is unclear. A randomized trial involving older patients (mean age 72 years) undergoing total hip or knee arthroplasty compared a low-intensity regimen of <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> (target INR 1.8) with a standard-intensity regimen (target INR 2.5) [<a href="#rid130">130</a>]. There was no difference in the rate of VTE or major bleeding, but interpretation is limited due to its open-label design and the low proportion of patients who achieved the target INR. Until further data are available, we continue to target an INR of 2.5.</p><p class="headingAnchor" id="H110334602"><span class="h3">Fondaparinux</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">Fondaparinux</a>, a factor Xa inhibitor, is a second-line agent for VTE prophylaxis in patients undergoing lower extremity major orthopedic surgery. It is an option in patients with HIT. Choosing an agent is described above. (See <a class="local">'Choosing an agent'</a> above.)</p><p>In this setting, <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> is given at a dose of 2.5 mg subcutaneously once daily. Fondaparinux is contraindicated in patients who weigh &lt;50 kg and avoided in those with renal insufficiency [<a href="#rid131">131</a>].</p><p>The efficacy of <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> has been evaluated in randomized trials and meta-analyses [<a href="#rid1">1,132-138</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In a 2016 meta-analysis of 25 trials including 21,000 mixed medical and surgical medical patients (most were undergoing major orthopedic surgery), <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> reduced the incidence of symptomatic VTE compared with placebo (0.2 versus 1.2 percent; RR 0.15, 95% CI 0.06-0.36) and increased the risk of major bleeding (1.2 versus 0.5 percent; RR 2.56, 95% CI 1.48-4.44) [<a href="#rid135">135</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In trials comparing <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> with LMW heparin, rates of symptomatic VTE were similar in both groups (0.6 percent in each; RR 1.03, 95% CI 0.65-1.63; nine trials), but major bleeding events were more common with fondaparinux (2.5 versus 1.8 percent; RR 1.38, 95% CI 1.09-1.75; 11 trials) [<a href="#rid135">135</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">Fondaparinux</a> has also been compared with DOACs. Retrospective studies report that DOACs (<a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a>, <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">edoxaban</a>) resulted in lower rates of VTE and either a similar or improved safety profile when compared with fondaparinux [<a href="#rid139">139,140</a>].</p><p></p><p>Extended-duration thromboprophylaxis with <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> was studied in a randomized trial of 656 patients undergoing hip fracture surgery [<a href="#rid141">141</a>]. Compared with a one-week treatment course, one month of fondaparinux reduced the incidence of symptomatic VTE (0.3 versus 2.7 percent). There was a nonsignificant trend toward an increase in major bleeding with extended therapy.</p><p>The use of <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> in patients with HIT is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1369.html" rel="external">"Management of heparin-induced thrombocytopenia", section on 'Fondaparinux'</a>.)</p><p class="headingAnchor" id="H2872093628"><span class="h1">PATIENTS WITH UNACCEPTABLY HIGH BLEEDING RISK</span><span class="headingEndMark"> — </span>For patients with an unacceptably high risk of bleeding and/or contraindications to pharmacologic thromboprophylaxis  (<a class="graphic graphic_table graphicRef107527" href="/z/d/graphic/107527.html" rel="external">table 3</a>), we suggest mechanical thromboprophylaxis. Among the options, we prefer intermittent pneumatic compression (IPC) devices. Vena cava filters should <strong>not</strong> be routinely used in this setting.</p><p>Mechanical methods are less effective than pharmacologic prophylaxis. Thus, it is important to switch to or add a pharmacologic agent as soon as hemostasis is assessed as adequate, bleeding risk becomes acceptably low, and/or the bleeding diathesis has been reversed. Mechanical methods are also frequently used in combination with pharmacologic methods, although there are limited data to support this practice. (See <a class="local">'Approach to pharmacologic thromboprophylaxis (low-risk bleeding)'</a> above and <a class="local">'Role of combined pharmacologic and mechanical thromboprophylaxis'</a> above.)</p><p class="headingAnchor" id="H1559898582"><span class="h2">Mechanical prophylaxis</span><span class="headingEndMark"> — </span>Mechanical prophylaxis devices are effective for reducing the risk of VTE in this population and are appropriate for patients who cannot receive pharmacologic prophylaxis [<a href="#rid1">1</a>]. However, mechanical prophylaxis alone is generally less effective with regimens that contain pharmacologic prophylaxis [<a href="#rid126">126-129,142,143</a>].</p><p class="headingAnchor" id="H2779591423"><span class="h3">Devices</span><span class="headingEndMark"> — </span>Options for mechanical thromboprophylaxis include IPC, graduated compression stockings (GCS), and the venous foot pump (VFP). We prefer IPC since there are more data supporting its use in orthopedic patients [<a href="#rid1">1</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>IPC</strong> – Data supporting the use of IPC for the prevention of VTE in orthopedic surgical patients are limited and subject to bias due to lack of blinding and small numbers. Nevertheless, the available data suggest that IPC may reduce the incidence of VTE (symptomatic and asymptomatic) by as much as 50 percent compared with no prophylaxis.</p><p></p><p class="bulletIndent1">Several small trials of patients undergoing total hip arthroplasty, total knee arthroplasty, or hip fracture surgery compared IPC with no thromboprophylaxis and, in general, demonstrated a reduction in the rate of deep venous thrombosis (DVT) [<a href="#rid42">42,144-147</a>]. As an example, in a randomized trial of 310 patients who underwent total hip arthroplasty, IPC reduced the rate of venographic DVT from 49 to 24 percent and proximal DVT from 27 to 14 percent [<a href="#rid144">144</a>]. It is noteworthy that the residual rates of DVT were still high despite mechanical prophylaxis. Studies that suggest inferiority of IPC compared with low molecular weight heparin or <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> are discussed separately. (See <a class="local">'Low molecular weight heparin'</a> above and <a class="local">'Warfarin'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>GCS</strong> – Evidence to support the use of GCS is derived from indirect data in other surgical and medical patients; outcome associated with the use of GCS in those populations is mixed and associated with an increase in the risk of local skin complications. Only one small trial in orthopedic patients has been performed and showed a similar lack of benefit [<a href="#rid148">148</a>]. Nonetheless, they are frequently used in combination with pharmacologic methods in high-risk patients undergoing orthopedic surgery. (See  <a class="medical medical_review" href="/z/d/html/121857.html" rel="external">"Prevention and treatment of venous thromboembolism in patients with acute stroke", section on 'Ineffective or unproven treatments'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>VFP</strong> – Several small studies suggest that VFP devices may be effective in reducing the incidence of VTE in patients undergoing major orthopedic surgery, although data are biased and have small numbers [<a href="#rid149">149-154</a>]. (See  <a class="medical medical_review" href="/z/d/html/113028.html" rel="external">"Venous thromboembolism risk and prevention in the severely injured trauma patient"</a>.)</p><p></p><p class="headingAnchor" id="H1690254415"><span class="h3">Placement and timing of devices</span><span class="headingEndMark"> — </span>For patients in whom mechanical methods (IPC, GCS, VFP) are indicated, devices are typically placed on the patient just prior to the start of surgery and used continuously postoperatively until hospital discharge, ambulation, or pharmacologic thromboprophylaxis is initiated.</p><p>If a mechanical device cannot be applied to the operated lower extremity, it can be applied to the contralateral extremity to decrease the risk for DVT (up to 20 percent of DVT occur in the nonoperated leg) and may theoretically prevent DVT in both lower extremities.</p><p>Although most operating rooms have mechanical devices, compliance postoperatively may be poor [<a href="#rid155">155,156</a>]. However, portable battery-powered devices may improve compliance [<a href="#rid157">157</a>].</p><p>Adverse effects including skin breakdown and contraindications to device use are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">"Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients", section on 'Intermittent pneumatic compression and venous foot pump'</a>.)</p><p class="headingAnchor" id="H511969145"><span class="h2">No role for vena cava filters</span><span class="headingEndMark"> — </span>Prophylactic inferior vena cava (IVC) filters should <strong>not</strong> be routinely used in this setting. The risks of IVC filter placement are unacceptably high relative to the risk of VTE in this population. (See  <a class="medical medical_review" href="/z/d/html/8212.html" rel="external">"Placement of vena cava filters and their complications"</a>.)</p><p class="headingAnchor" id="H1705444868"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113663.html" rel="external">"Society guideline links: Superficial vein thrombosis, deep vein thrombosis, and pulmonary embolism"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/114614.html" rel="external">"Society guideline links: Anticoagulation"</a>.)</p><p class="headingAnchor" id="H430241557"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>The Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15362.html" rel="external">"Patient education: Deep vein thrombosis (blood clot in the leg) (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/16922.html" rel="external">"Patient education: Pulmonary embolism (blood clot in the lung) (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/16265.html" rel="external">"Patient education: Choosing an oral medicine for blood clots (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/86638.html" rel="external">"Patient education: Taking oral medicines for blood clots (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/693.html" rel="external">"Patient education: Deep vein thrombosis (DVT) (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/696.html" rel="external">"Patient education: Pulmonary embolism (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/689.html" rel="external">"Patient education: Warfarin (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H9926118"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk assessment</strong> – Patients undergoing major lower extremity orthopedic surgery (eg, total or partial hip arthroplasty, total or partial knee arthroplasty, hip fracture surgery) should be assessed for risk of venous thromboembolism (VTE; lower extremity deep venous thrombosis and pulmonary embolism) and risk of bleeding. (See <a class="local">'Risk assessment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Major lower extremity orthopedic surgery is associated with a higher risk of symptomatic VTE compared with most other surgeries, with an estimated incidence of approximately 4 percent. The risk is greatest in the first 7 to 14 days.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The risk of major bleeding is also high relative to other surgeries, with an estimated rate of 2 to 4 percent.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Additional individual risk factors for VTE (eg, previous VTE) and bleeding (eg, thrombocytopenia) can further increase the baseline risk. In most cases, the bleeding risk is not so high as to preclude use of pharmacologic thromboprophylaxis unless the patient has a specific contraindication  (<a class="graphic graphic_table graphicRef107527" href="/z/d/graphic/107527.html" rel="external">table 3</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients at low risk of bleeding</strong> – For patients undergoing major lower extremity orthopedic surgery who are at low risk of bleeding, we recommend pharmacologic thromboprophylaxis with or without intermittent pneumatic compression (IPC) devices rather than no thromboprophylaxis (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). The choice of <strong>initial</strong> agent is influenced by the type of surgery and comorbidities  (<a class="graphic graphic_algorithm graphicRef140146" href="/z/d/graphic/140146.html" rel="external">algorithm 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients undergoing knee or hip arthroplasty</strong> – For most patients undergoing knee or hip arthroplasty, we suggest low molecular weight (LMW) heparin or a direct oral anticoagulant (DOAC) as the initial agent in the early perioperative period (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>) (ie, the immediate postoperative period and up to 14 days thereafter).</p><p></p><p class="bulletIndent2"><a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">Enoxaparin</a> or <a class="drug drug_general" data-topicid="9319" href="/z/d/drug information/9319.html" rel="external">dalteparin</a> are LMW heparin agents that are well studied and commonly used. Among the DOACs, we suggest <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a> or <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">apixaban</a> rather than <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">dabigatran</a> or <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">edoxaban</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>) since there are more data to support their use in this setting.</p><p></p><p class="bulletIndent2">While we prefer <strong>not</strong> to use <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> as the sole initial agent for VTE prophylaxis in the early postoperative period, many orthopedic surgeons have adopted this practice viewing it as an effective and safe agent. However, the typical dosing used varies in practice and further data are needed before we feel this approach should be routinely used. We are, however, proponents of switching to aspirin after a short course of anticoagulant therapy, which is discussed in the bullet "Duration of pharmacologic prophylaxis" below. Dosing and efficacy of these agents are provided above. (See <a class="local">'Low molecular weight heparin'</a> above and <a class="local">'Direct oral anticoagulants'</a> above and <a class="local">'Aspirin'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients undergoing hip fracture surgery</strong> – For most patients undergoing hip fracture surgery, we suggest LMW heparin as the preferred agent for the entire duration of prophylaxis (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We generally avoid DOACs in this setting since their safety and efficacy have not been studied in this population. Limited observational data suggest that <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> may be an appropriate alternative in select low-risk patients who undergo surgery for lower extremity trauma (eg, polytrauma in young males). (See <a class="local">'Low molecular weight heparin'</a> above and  <a class="medical medical_review" href="/z/d/html/113028.html" rel="external">"Venous thromboembolism risk and prevention in the severely injured trauma patient"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with renal failure</strong> – Options for patients with severe renal failure (eg, creatinine clearance &lt;30 mL/min or on hemodialysis) include <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">unfractionated heparin</a> (UFH) or <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>. In most cases, we suggest UFH (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). However, warfarin may be used if heparin injections are undesirable. Patients with less severe renal insufficiency can receive LMW heparin with appropriate dose adjustment and monitoring as summarized in the table  (<a class="graphic graphic_table graphicRef90258" href="/z/d/graphic/90258.html" rel="external">table 4</a>). (See <a class="local">'Unfractionated heparin'</a> above and <a class="local">'Warfarin'</a> above and <a class="local">'Low molecular weight heparin'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with heparin-induced thrombocytopenia (HIT)</strong> – Patients with HIT or history of HIT should be treated with a nonheparin agent, the details of which are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1369.html" rel="external">"Management of heparin-induced thrombocytopenia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timing of pharmacologic agents</strong> – If LMW heparin is selected for initial pharmacologic prophylaxis, it is typically started preoperatively with an initial dose ≥12 hours before surgery and then continued postoperatively with a second dose ≥12 hours after surgery. Oral agents are generally started 6 to 12 hours or more after surgery, provided that the patient can eat. (See <a class="local">'Timing of initiation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of pharmacologic prophylaxis</strong> – For most patients, we suggest that the initial thromboprophylaxis agent be continued for a <strong>minimum</strong> of 10 to 14 days  (<a class="graphic graphic_algorithm graphicRef140147" href="/z/d/graphic/140147.html" rel="external">algorithm 2</a>) (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). Longer or shorter duration may be appropriate depending on the surgery and other risk factors (see <a class="local">'Duration'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hip arthroplasty</strong> – For patients undergoing total hip arthroplasty, we suggest extending thromboprophylaxis for a total of 35 days (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). For most patients, the same agent is used for the entire 35-day course (typically LMW heparin or a DOAC). However, for select lower-risk patients, we suggest transitioning to <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> after 5 to 10 days of initial therapy with LMW heparin or DOAC and completing the remainder of the 35-day course with aspirin alone (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). Lower-risk patients are considered as those who fill all of the following criteria: no other risk factors for VTE, no other indications for long-term anticoagulation, no lower limb or hip fracture in the previous three months, surgery is elective and unilateral, and the patient is ambulatory within 24 hours after surgery. (See <a class="local">'Duration'</a> above and <a class="local">'Aspirin'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Knee arthroplasty</strong> – For most patients undergoing total knee arthroplasty who are fully ambulatory and discharged to home within 10 to 14 days, we suggest <strong>not</strong> extending thromboprophylaxis beyond 14 days (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). For lower-risk patients (as defined in the previous bullet), we suggest transitioning to <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> after five days of initial therapy with LMW heparin or DOAC and completing the remainder of the 10- to 14-day course with aspirin alone (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). For other patients, LMW heparin or DOAC prophylaxis is continued for the full 10- to 14-day course. In patients who are not yet ambulatory by 14 days, LMW heparin or DOAC prophylaxis is continued until fully ambulatory or 35 days, whichever is shorter. (See <a class="local">'Duration'</a> above and <a class="local">'Aspirin'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hip fracture surgery</strong> – For patients undergoing hip fracture surgery, we suggest extending thromboprophylaxis for a total of 35 days (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). The same agent is used for the entire 35-day course (typically LMW heparin).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with contraindications to pharmacologic thromboprophylaxis</strong> <strong>or at high risk of bleeding</strong> – For patients with an unacceptably high risk of bleeding from pharmacologic thromboprophylaxis  (<a class="graphic graphic_table graphicRef107527" href="/z/d/graphic/107527.html" rel="external">table 3</a>), we suggest mechanical methods rather than no thromboprophylaxis (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). We suggest IPC devices rather than other methods (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>) since there are more available data on their use in this setting. Vena cava filters should <strong>not</strong> be routinely used. Mechanical devices are typically placed on the patient just prior to the start of surgery and continued until ambulation, discharge, or transition to pharmacologic thromboprophylaxis. Mechanical methods are less effective than pharmacologic prophylaxis, and it is important to switch to or add a pharmacologic agent as soon as bleeding risk becomes acceptably low. (See <a class="local">'Patients with unacceptably high bleeding risk'</a> above.)</p><p></p><p class="headingAnchor" id="H1312133399"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Menaka Pai, MD, FRCPC, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e278S.</a></li><li><a class="nounderline abstract_t">Anderson DR, Morgano GP, Bennett C, et al. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. Blood Adv 2019; 3:3898.</a></li><li><a class="nounderline abstract_t">Guyatt GH, Akl EA, Crowther M, et al. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:7S.</a></li><li><a class="nounderline abstract_t">Douketis JD, Spyropoulos AC, Murad MH, et al. Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline. Chest 2022; 162:e207.</a></li><li><a class="nounderline abstract_t">Douketis JD, Spyropoulos AC, Murad MH, et al. Executive Summary: Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline. Chest 2022; 162:1127.</a></li><li><a class="nounderline abstract_t">Bateman DK, Dow RW, Brzezinski A, et al. Correlation of the Caprini Score and Venous Thromboembolism Incidence Following Primary Total Joint Arthroplasty-Results of a Single-Institution Protocol. J Arthroplasty 2017; 32:3735.</a></li><li><a class="nounderline abstract_t">Bjørnarå BT, Gudmundsen TE, Dahl OE. Frequency and timing of clinical venous thromboembolism after major joint surgery. J Bone Joint Surg Br 2006; 88:386.</a></li><li><a class="nounderline abstract_t">Januel JM, Chen G, Ruffieux C, et al. Symptomatic in-hospital deep vein thrombosis and pulmonary embolism following hip and knee arthroplasty among patients receiving recommended prophylaxis: a systematic review. JAMA 2012; 307:294.</a></li><li><a class="nounderline abstract_t">White RH, Gettner S, Newman JM, et al. Predictors of rehospitalization for symptomatic venous thromboembolism after total hip arthroplasty. N Engl J Med 2000; 343:1758.</a></li><li><a class="nounderline abstract_t">White RH, Zhou H, Romano PS. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost 2003; 90:446.</a></li><li><a class="nounderline abstract_t">Pedersen AB, Sorensen HT, Mehnert F, et al. Risk factors for venous thromboembolism in patients undergoing total hip replacement and receiving routine thromboprophylaxis. J Bone Joint Surg Am 2010; 92:2156.</a></li><li><a class="nounderline abstract_t">Leizorovicz A, Turpie AG, Cohen AT, et al. Epidemiology of venous thromboembolism in Asian patients undergoing major orthopedic surgery without thromboprophylaxis. The SMART study. J Thromb Haemost 2005; 3:28.</a></li><li><a class="nounderline abstract_t">Mantilla CB, Horlocker TT, Schroeder DR, et al. Risk factors for clinically relevant pulmonary embolism and deep venous thrombosis in patients undergoing primary hip or knee arthroplasty. Anesthesiology 2003; 99:552.</a></li><li><a class="nounderline abstract_t">Samama CM, Ravaud P, Parent F, et al. Epidemiology of venous thromboembolism after lower limb arthroplasty: the FOTO study. J Thromb Haemost 2007; 5:2360.</a></li><li><a class="nounderline abstract_t">Chandrasekaran S, Ariaretnam SK, Tsung J, Dickison D. Early mobilization after total knee replacement reduces the incidence of deep venous thrombosis. ANZ J Surg 2009; 79:526.</a></li><li><a class="nounderline abstract_t">Sadeghi B, Romano PS, Maynard G, et al. Mechanical and suboptimal pharmacologic prophylaxis and delayed mobilization but not morbid obesity are associated with venous thromboembolism after total knee arthroplasty: a case-control study. J Hosp Med 2012; 7:665.</a></li><li><a class="nounderline abstract_t">Hill J, Treasure T, National Clinical Guideline Centre for Acute and Chronic Conditions. Reducing the risk of venous thromboembolism in patients admitted to hospital: summary of NICE guidance. BMJ 2010; 340:c95.</a></li><li><a class="nounderline abstract_t">Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3:692.</a></li><li><a class="nounderline abstract_t">Hull RD, Pineo GF, Francis C, et al. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin Trial Investigators. Arch Intern Med 2000; 160:2199.</a></li><li><a class="nounderline abstract_t">Hull RD, Pineo GF, Stein PD, et al. Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review. Arch Intern Med 2001; 161:1952.</a></li><li><a class="nounderline abstract_t">Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372:31.</a></li><li><a class="nounderline abstract_t">Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370:949.</a></li><li><a class="nounderline abstract_t">Lassen MR, Gallus A, Raskob GE, et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010; 363:2487.</a></li><li><a class="nounderline abstract_t">Anderson DR, Dunbar M, Murnaghan J, et al. Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty. N Engl J Med 2018; 378:699.</a></li><li><a class="nounderline abstract_t">Planes A, Vochelle N, Darmon JY, et al. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet 1996; 348:224.</a></li><li><a class="nounderline abstract_t">Bergqvist D, Benoni G, Björgell O, et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996; 335:696.</a></li><li><a class="nounderline abstract_t">Dahl OE, Andreassen G, Aspelin T, et al. Prolonged thromboprophylaxis following hip replacement surgery--results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin). Thromb Haemost 1997; 77:26.</a></li><li><a class="nounderline abstract_t">Lassen MR, Borris LC, Anderson BS, et al. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty--the Danish Prolonged Prophylaxis (DaPP) Study. Thromb Res 1998; 89:281.</a></li><li><a class="nounderline abstract_t">Comp PC, Spiro TE, Friedman RJ, et al. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group. J Bone Joint Surg Am 2001; 83-A:336.</a></li><li><a class="nounderline abstract_t">White RH, Romano PS, Zhou H, et al. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 1998; 158:1525.</a></li><li><a class="nounderline abstract_t">Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet 2001; 358:9.</a></li><li><a class="nounderline abstract_t">Hull RD, Pineo GF, Stein PD, et al. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med 2001; 135:858.</a></li><li><a class="nounderline abstract_t">Sobieraj DM, Lee S, Coleman CI, et al. Prolonged versus standard-duration venous thromboprophylaxis in major orthopedic surgery: a systematic review. Ann Intern Med 2012; 156:720.</a></li><li><a class="nounderline abstract_t">Fisher WD, Agnelli G, George DJ, et al. Extended venous thromboembolism prophylaxis in patients undergoing hip fracture surgery - the SAVE-HIP3 study. Bone Joint J 2013; 95-B:459.</a></li><li><a class="nounderline abstract_t">O'Donnell M, Linkins LA, Kearon C, et al. Reduction of out-of-hospital symptomatic venous thromboembolism by extended thromboprophylaxis with low-molecular-weight heparin following elective hip arthroplasty: a systematic review. Arch Intern Med 2003; 163:1362.</a></li><li><a class="nounderline abstract_t">Forster R, Stewart M. Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair. Cochrane Database Syst Rev 2016; 3:CD004179.</a></li><li><a class="nounderline abstract_t">Heit JA, Elliott CG, Trowbridge AA, et al. Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2000; 132:853.</a></li><li><a class="nounderline abstract_t">Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358:2765.</a></li><li><a class="nounderline abstract_t">Petersen PB, Kehlet H, Jørgensen CC, Lundbeck Foundation Centre for Fast-track Hip and Knee Replacement Collaborative Group. Safety of In-Hospital Only Thromboprophylaxis after Fast-Track Total Hip and Knee Arthroplasty: A Prospective Follow-Up Study in 17,582 Procedures. Thromb Haemost 2018; 118:2152.</a></li><li><a class="nounderline abstract_t">Fuji T, Fujita S, Kimura T, et al. Clinical benefit of graduated compression stockings for prevention of venous thromboembolism after total knee arthroplasty: post hoc analysis of a phase 3 clinical study of edoxaban. Thromb J 2016; 14:13.</a></li><li><a class="nounderline abstract_t">Snyder MA, Sympson AN, Scheuerman CM, et al. Efficacy in Deep Vein Thrombosis Prevention With Extended Mechanical Compression Device Therapy and Prophylactic Aspirin Following Total Knee Arthroplasty: A Randomized Control Trial. J Arthroplasty 2017; 32:1478.</a></li><li><a class="nounderline abstract_t">Kwak HS, Cho JH, Kim JT, et al. Intermittent Pneumatic Compression for the Prevention of Venous Thromboembolism after Total Hip Arthroplasty. Clin Orthop Surg 2017; 9:37.</a></li><li class="breakAll">Enoxaparin (Lovenox) US FDA approved product information https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020164s110lbl.pdf (Accessed on February 03, 2018).</li><li class="breakAll">Dalteparin (Fragmin) US FDA approved product information (May, 2017 revision) https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020287s069lbl.pdf. (Accessed on February 04, 2018).</li><li><a class="nounderline abstract_t">Hoy SM, Scott LJ, Plosker GL. Tinzaparin sodium: a review of its use in the prevention and treatment of deep vein thrombosis and pulmonary embolism, and in the prevention of clotting in the extracorporeal circuit during haemodialysis. Drugs 2010; 70:1319.</a></li><li class="breakAll">Tinzaparin (Innohep) Summary of product characteristics (United Kingdom) https://www.medicines.org.uk/emc/product/3632 (Accessed on February 03, 2018).</li><li class="breakAll">Nadroparin (Fraxiparine) Health Canada Product Monograph https://health-products.canada.ca/dpd-bdpp/index-eng.jsp (Accessed on February 03, 2018).</li><li><a class="nounderline abstract_t">Fuji T, Ochi T, Niwa S, Fujita S. Prevention of postoperative venous thromboembolism in Japanese patients undergoing total hip or knee arthroplasty: two randomized, double-blind, placebo-controlled studies with three dosage regimens of enoxaparin. J Orthop Sci 2008; 13:442.</a></li><li><a class="nounderline abstract_t">Leclerc JR, Geerts WH, Desjardins L, et al. Prevention of deep vein thrombosis after major knee surgery--a randomized, double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to placebo. Thromb Haemost 1992; 67:417.</a></li><li><a class="nounderline abstract_t">Levine MN, Gent M, Hirsh J, et al. Ardeparin (low-molecular-weight heparin) vs graduated compression stockings for the prevention of venous thromboembolism. A randomized trial in patients undergoing knee surgery. Arch Intern Med 1996; 156:851.</a></li><li><a class="nounderline abstract_t">Turpie AG, Levine MN, Hirsh J, et al. A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 1986; 315:925.</a></li><li><a class="nounderline abstract_t">Jørgensen PS, Knudsen JB, Broeng L, et al. The thromboprophylactic effect of a low-molecular-weight heparin (Fragmin) in hip fracture surgery. A placebo-controlled study. Clin Orthop Relat Res 1992; :95.</a></li><li><a class="nounderline abstract_t">Kapoor A, Ellis A, Shaffer N, et al. Comparative effectiveness of venous thromboembolism prophylaxis options for the patient undergoing total hip and knee replacement: a network meta-analysis. J Thromb Haemost 2017; 15:284.</a></li><li><a class="nounderline abstract_t">Hull R, Raskob G, Pineo G, et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med 1993; 329:1370.</a></li><li><a class="nounderline abstract_t">RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty. RD Heparin Arthroplasty Group. J Bone Joint Surg Am 1994; 76:1174.</a></li><li><a class="nounderline abstract_t">Leclerc JR, Geerts WH, Desjardins L, et al. Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin. Ann Intern Med 1996; 124:619.</a></li><li><a class="nounderline abstract_t">Fitzgerald RH Jr, Spiro TE, Trowbridge AA, et al. Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin. J Bone Joint Surg Am 2001; 83-A:900.</a></li><li><a class="nounderline abstract_t">Hamulyák K, Lensing AW, van der Meer J, et al. Subcutaneous low-molecular weight heparin or oral anticoagulants for the prevention of deep-vein thrombosis in elective hip and knee replacement? Fraxiparine Oral Anticoagulant Study Group. Thromb Haemost 1995; 74:1428.</a></li><li><a class="nounderline abstract_t">Mismetti P, Laporte S, Zufferey P, et al. Prevention of venous thromboembolism in orthopedic surgery with vitamin K antagonists: a meta-analysis. J Thromb Haemost 2004; 2:1058.</a></li><li><a class="nounderline abstract_t">Raskob GE, Hirsh J. Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery. Chest 2003; 124:379S.</a></li><li><a class="nounderline abstract_t">Francis CW, Pellegrini VD Jr, Totterman S, et al. Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin. J Bone Joint Surg Am 1997; 79:1365.</a></li><li><a class="nounderline abstract_t">Colwell CW Jr, Collis DK, Paulson R, et al. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge. J Bone Joint Surg Am 1999; 81:932.</a></li><li><a class="nounderline abstract_t">Samama CM, Vray M, Barré J, et al. Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low-molecular-weight heparin with oral anticoagulant. Arch Intern Med 2002; 162:2191.</a></li><li><a class="nounderline abstract_t">Hull RD, Pineo GF, Francis C, et al. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators. Arch Intern Med 2000; 160:2208.</a></li><li><a class="nounderline abstract_t">Levine MN, Hirsh J, Gent M, et al. Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med 1991; 114:545.</a></li><li><a class="nounderline abstract_t">Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 1988; 318:1162.</a></li><li><a class="nounderline abstract_t">Karthikeyan G, Eikelboom JW, Turpie AG, Hirsh J. Does acetyl salicylic acid (ASA) have a role in the prevention of venous thromboembolism? Br J Haematol 2009; 146:142.</a></li><li><a class="nounderline abstract_t">Imperiale TF, Speroff T. A meta-analysis of methods to prevent venous thromboembolism following total hip replacement. JAMA 1994; 271:1780.</a></li><li><a class="nounderline abstract_t">Westrich GH, Bottner F, Windsor RE, et al. VenaFlow plus Lovenox vs VenaFlow plus aspirin for thromboembolic disease prophylaxis in total knee arthroplasty. J Arthroplasty 2006; 21:139.</a></li><li><a class="nounderline abstract_t">Drescher FS, Sirovich BE, Lee A, et al. Aspirin versus anticoagulation for prevention of venous thromboembolism major lower extremity orthopedic surgery: a systematic review and meta-analysis. J Hosp Med 2014; 9:579.</a></li><li><a class="nounderline abstract_t">CRISTAL Study Group, Sidhu VS, Kelly TL, et al. Effect of Aspirin vs Enoxaparin on Symptomatic Venous Thromboembolism in Patients Undergoing Hip or Knee Arthroplasty: The CRISTAL Randomized Trial. JAMA 2022; 328:719.</a></li><li><a class="nounderline abstract_t">Camporese G, Bernardi E, Prandoni P, et al. Low-molecular-weight heparin versus compression stockings for thromboprophylaxis after knee arthroscopy: a randomized trial. Ann Intern Med 2008; 149:73.</a></li><li><a class="nounderline abstract_t">Pitto RP, Hamer H, Heiss-Dunlop W, Kuehle J. Mechanical prophylaxis of deep-vein thrombosis after total hip replacement a randomised clinical trial. J Bone Joint Surg Br 2004; 86:639.</a></li><li><a class="nounderline abstract_t">Stone MH, Limb D, Campbell P, et al. A comparison of intermittent calf compression and enoxaparin for thromboprophylaxis in total hip replacement. A pilot study. Int Orthop 1996; 20:367.</a></li><li><a class="nounderline abstract_t">Warwick D, Harrison J, Glew D, et al. Comparison of the use of a foot pump with the use of low-molecular-weight heparin for the prevention of deep-vein thrombosis after total hip replacement. A prospective, randomized trial. J Bone Joint Surg Am 1998; 80:1158.</a></li><li><a class="nounderline abstract_t">Blanchard J, Meuwly JY, Leyvraz PF, et al. Prevention of deep-vein thrombosis after total knee replacement. Randomised comparison between a low-molecular-weight heparin (nadroparin) and mechanical prophylaxis with a foot-pump system. J Bone Joint Surg Br 1999; 81:654.</a></li><li class="breakAll">http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/022512Orig1s028ltr.pdf (Accessed on December 01, 2015).</li><li class="breakAll">http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022512s028lbl.pdf (Accessed on December 01, 2015).</li><li><a class="nounderline abstract_t">Martin KA, Beyer-Westendorf J, Davidson BL, et al. Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation. J Thromb Haemost 2021; 19:1874.</a></li><li><a class="nounderline abstract_t">Nieto JA, Espada NG, Merino RG, González TC. Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials. Thromb Res 2012; 130:183.</a></li><li><a class="nounderline abstract_t">Huisman MV, Quinlan DJ, Dahl OE, Schulman S. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials. Circ Cardiovasc Qual Outcomes 2010; 3:652.</a></li><li><a class="nounderline abstract_t">Neumann I, Rada G, Claro JC, et al. Oral direct Factor Xa inhibitors versus low-molecular-weight heparin to prevent venous thromboembolism in patients undergoing total hip or knee replacement: a systematic review and meta-analysis. Ann Intern Med 2012; 156:710.</a></li><li><a class="nounderline abstract_t">Venous Thromboembolism Prophylaxis in Orthopedic Surgery [Internet]. Publication number 12-EHC020-EF. AHRQ Comparative Effectiveness Reviews 2012.</a></li><li><a class="nounderline abstract_t">Gómez-Outes A, Terleira-Fernández AI, Suárez-Gea ML, Vargas-Castrillón E. Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons. BMJ 2012; 344:e3675.</a></li><li><a class="nounderline abstract_t">Loke YK, Kwok CS. Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison. J Clin Pharm Ther 2011; 36:111.</a></li><li><a class="nounderline abstract_t">Adam S, McDuffie J, Lachiewicz P, et al. Comparative Effectiveness of New Oral Anticoagulants and Standard Thromboprophylaxis in Patients Having Total Hip or Knee Replacement: A Systematic Review. Ann Intern Med 2013; 159:275.</a></li><li><a class="nounderline abstract_t">Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358:2776.</a></li><li><a class="nounderline abstract_t">Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009; 373:1673.</a></li><li><a class="nounderline abstract_t">Eriksson BI, Borris LC, Dahl OE, et al. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation 2006; 114:2374.</a></li><li><a class="nounderline abstract_t">Turpie AG, Fisher WD, Bauer KA, et al. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost 2005; 3:2479.</a></li><li><a class="nounderline abstract_t">Eriksson BI, Borris L, Dahl OE, et al. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2006; 4:121.</a></li><li><a class="nounderline abstract_t">Turpie AG, Lassen MR, Eriksson BI, et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost 2011; 105:444.</a></li><li><a class="nounderline abstract_t">Eriksson BI, Dahl OE, Ahnfelt L, et al. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. J Thromb Haemost 2004; 2:1573.</a></li><li><a class="nounderline abstract_t">Eriksson BI, Dahl OE, Büller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005; 3:103.</a></li><li><a class="nounderline abstract_t">Wolowacz SE, Roskell NS, Plumb JM, et al. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost 2009; 101:77.</a></li><li><a class="nounderline abstract_t">Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 5:2178.</a></li><li><a class="nounderline abstract_t">RE-MOBILIZE Writing Committee, Ginsberg JS, Davidson BL, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009; 24:1.</a></li><li><a class="nounderline abstract_t">Fuji T, Wang CJ, Fujita S, et al. Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial. Thromb Res 2014; 134:1198.</a></li><li><a class="nounderline abstract_t">Fuji T, Fujita S, Kawai Y, et al. A randomized, open-label trial of edoxaban in Japanese patients with severe renal impairment undergoing lower-limb orthopedic surgery. Thromb J 2015; 13:6.</a></li><li class="breakAll">http://www.discoverymedicine.com/Ingo-Ahrens/2012/06/23/development-and-clinical-applications-of-novel-oral-anticoagulants-part-i-clinically-approved-drugs/ (Accessed on November 07, 2012).</li><li><a class="nounderline abstract_t">Hull RD, Liang J, Bergqvist D, Yusen RD. Benefit-to-harm ratio of thromboprophylaxis for patients undergoing major orthopaedic surgery. A systematic review. Thromb Haemost 2014; 111:199.</a></li><li><a class="nounderline abstract_t">Kim SM, Moon YW, Lim SJ, et al. Effect of oral factor Xa inhibitor and low-molecular-weight heparin on surgical complications following total hip arthroplasty. Thromb Haemost 2016; 115:600.</a></li><li><a class="nounderline abstract_t">Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009; 361:594.</a></li><li><a class="nounderline abstract_t">Lassen MR, Davidson BL, Gallus A, et al. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 2007; 5:2368.</a></li><li><a class="nounderline abstract_t">Lassen MR, Raskob GE, Gallus A, et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010; 375:807.</a></li><li><a class="nounderline abstract_t">Kawai Y, Fuji T, Fujita S, et al. Edoxaban versus enoxaparin for the prevention of venous thromboembolism after total knee or hip arthroplasty: pooled analysis of coagulation biomarkers and primary efficacy and safety endpoints from two phase 3 trials. Thromb J 2016; 14:48.</a></li><li><a class="nounderline abstract_t">Cohen AT, Hamilton M, Mitchell SA, et al. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis. PLoS One 2015; 10:e0144856.</a></li><li><a class="nounderline abstract_t">Jenny JY, Pabinger I, Samama CM, ESA VTE Guidelines Task Force. European guidelines on perioperative venous thromboembolism prophylaxis: Aspirin. Eur J Anaesthesiol 2018; 35:123.</a></li><li><a class="nounderline abstract_t">Major Extremity Trauma Research Consortium (METRC), O'Toole RV, Stein DM, et al. Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture. N Engl J Med 2023; 388:203.</a></li><li><a class="nounderline abstract_t">Anderson DR, Dunbar MJ, Bohm ER, et al. Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. Ann Intern Med 2013; 158:800.</a></li><li><a class="nounderline abstract_t">Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 2000; 355:1295.</a></li><li><a class="nounderline abstract_t">Parvizi J, Huang R, Restrepo C, et al. Low-Dose Aspirin Is Effective Chemoprophylaxis Against Clinically Important Venous Thromboembolism Following Total Joint Arthroplasty: A Preliminary Analysis. J Bone Joint Surg Am 2017; 99:91.</a></li><li><a class="nounderline abstract_t">Azboy I, Groff H, Goswami K, et al. Low-Dose Aspirin Is Adequate for Venous Thromboembolism Prevention Following Total Joint Arthroplasty: A Systematic Review. J Arthroplasty 2020; 35:886.</a></li><li><a class="nounderline abstract_t">Matharu GS, Kunutsor SK, Judge A, et al. Clinical Effectiveness and Safety of Aspirin for Venous Thromboembolism Prophylaxis After Total Hip and Knee Replacement: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Intern Med 2020; 180:376.</a></li><li><a class="nounderline abstract_t">Hood BR, Cowen ME, Zheng HT, et al. Association of Aspirin With Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty Compared With Other Anticoagulants: A Noninferiority Analysis. JAMA Surg 2019; 154:65.</a></li><li><a class="nounderline abstract_t">Goel R, Fleischman AN, Tan T, et al. Venous thromboembolic prophylaxis after simultaneous bilateral total knee arthroplasty: aspirin versus warfarin. Bone Joint J 2018; 100-B:68.</a></li><li><a class="nounderline abstract_t">Rondon AJ, Shohat N, Tan TL, et al. The Use of Aspirin for Prophylaxis Against Venous Thromboembolism Decreases Mortality Following Primary Total Joint Arthroplasty. J Bone Joint Surg Am 2019; 101:504.</a></li><li><a class="nounderline abstract_t">Chisari E, Tan TL, Shah R, et al. Aspirin Is an Effective Prophylaxis for Venous Thromboembolism in Ambulatory Patients with Femoral Neck Fracture Undergoing Hip Arthroplasty. J Bone Joint Surg Am 2022; 104:603.</a></li><li><a class="nounderline abstract_t">Powers PJ, Gent M, Jay RM, et al. A randomized trial of less intense postoperative warfarin or aspirin therapy in the prevention of venous thromboembolism after surgery for fractured hip. Arch Intern Med 1989; 149:771.</a></li><li><a class="nounderline abstract_t">Joy M, Tharp E, Hartman H, et al. Safety and Efficacy of High-Dose Unfractionated Heparin for Prevention of Venous Thromboembolism in Overweight and Obese Patients. Pharmacotherapy 2016; 36:740.</a></li><li><a class="nounderline abstract_t">Wang TF, Milligan PE, Wong CA, et al. Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients. Thromb Haemost 2014; 111:88.</a></li><li><a class="nounderline abstract_t">Clark NP, Cho SE, Delate T, Witt DM. Thromboembolic and bleeding outcomes of low-intensity warfarin thromboprophylaxis following elective total hip arthroplasty. Thromb Res 2013; 131:390.</a></li><li><a class="nounderline abstract_t">Cho SE, Delate T, Witt DM, Clark NP. Thromboembolic and bleeding outcomes of extended duration low-intensity warfarin following elective total knee arthroplasty. Thromb Res 2015; 135:267.</a></li><li><a class="nounderline abstract_t">Nordstrom BL, Kachroo S, Fraeman KH, et al. Warfarin prophylaxis in patients after total knee or hip arthroplasty--international normalized ratio patterns and venous thromboembolism. Curr Med Res Opin 2011; 27:1973.</a></li><li><a class="nounderline abstract_t">Morris GK, Mitchell JR. Warfarin sodium in prevention of deep venous thrombosis and pulmonary embolism in patients with fractured neck of femur. Lancet 1976; 2:869.</a></li><li><a class="nounderline abstract_t">Bailey JP, Kruger MP, Solano FX, et al. Prospective randomized trial of sequential compression devices vs low-dose warfarin for deep venous thrombosis prophylaxis in total hip arthroplasty. J Arthroplasty 1991; 6 Suppl:S29.</a></li><li><a class="nounderline abstract_t">Francis CW, Pellegrini VD Jr, Marder VJ, et al. Comparison of warfarin and external pneumatic compression in prevention of venous thrombosis after total hip replacement. JAMA 1992; 267:2911.</a></li><li><a class="nounderline abstract_t">Paiement G, Wessinger SJ, Waltman AC, Harris WH. Low-dose warfarin versus external pneumatic compression for prophylaxis against venous thromboembolism following total hip replacement. J Arthroplasty 1987; 2:23.</a></li><li><a class="nounderline abstract_t">Kaempffe FA, Lifeso RM, Meinking C. Intermittent pneumatic compression versus coumadin. Prevention of deep vein thrombosis in lower-extremity total joint arthroplasty. Clin Orthop Relat Res 1991; :89.</a></li><li><a class="nounderline abstract_t">Gage BF, Bass AR, Lin H, et al. Effect of Low-Intensity vs Standard-Intensity Warfarin Prophylaxis on Venous Thromboembolism or Death Among Patients Undergoing Hip or Knee Arthroplasty: A Randomized Clinical Trial. JAMA 2019; 322:834.</a></li><li><a class="nounderline abstract_t">Garcia DA, Baglin TP, Weitz JI, et al. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e24S.</a></li><li><a class="nounderline abstract_t">Turpie AG, Bauer KA, Eriksson BI, et al. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002; 359:1721.</a></li><li><a class="nounderline abstract_t">Bauer KA, Eriksson BI, Lassen MR, et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001; 345:1305.</a></li><li><a class="nounderline abstract_t">Eriksson BI, Bauer KA, Lassen MR, et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001; 345:1298.</a></li><li><a class="nounderline abstract_t">Dong K, Song Y, Li X, et al. Pentasaccharides for the prevention of venous thromboembolism. Cochrane Database Syst Rev 2016; 10:CD005134.</a></li><li><a class="nounderline abstract_t">Lassen MR, Bauer KA, Eriksson BI, et al. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 2002; 359:1715.</a></li><li><a class="nounderline abstract_t">Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002; 162:1833.</a></li><li><a class="nounderline abstract_t">Colwell CW Jr, Kwong LM, Turpie AG, Davidson BL. Flexibility in administration of fondaparinux for prevention of symptomatic venous thromboembolism in orthopaedic surgery. J Arthroplasty 2006; 21:36.</a></li><li><a class="nounderline abstract_t">Beyer-Westendorf J, Lützner J, Donath L, et al. Efficacy and safety of rivaroxaban or fondaparinux thromboprophylaxis in major orthopedic surgery: findings from the ORTHO-TEP registry. J Thromb Haemost 2012; 10:2045.</a></li><li><a class="nounderline abstract_t">Sasaki H, Ishida K, Shibanuma N, et al. Retrospective comparison of three thromboprophylaxis agents, edoxaban, fondaparinux, and enoxaparin, for preventing venous thromboembolism in total knee arthroplasty. Int Orthop 2014; 38:525.</a></li><li><a class="nounderline abstract_t">Eriksson BI, Lassen MR, PENTasaccharide in HIp-FRActure Surgery Plus Investigators. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med 2003; 163:1337.</a></li><li><a class="nounderline abstract_t">Kakkos SK, Caprini JA, Geroulakos G, et al. Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism in high-risk patients. Cochrane Database Syst Rev 2008; :CD005258.</a></li><li class="breakAll">Safer Healthcare Now www.saferhealthcarenow.ca (Accessed on May 02, 2011).</li><li><a class="nounderline abstract_t">Hull RD, Raskob GE, Gent M, et al. Effectiveness of intermittent pneumatic leg compression for preventing deep vein thrombosis after total hip replacement. JAMA 1990; 263:2313.</a></li><li><a class="nounderline abstract_t">Wilson NV, Das SK, Kakkar VV, et al. Thrombo-embolic prophylaxis in total knee replacement. Evaluation of the A-V Impulse System. J Bone Joint Surg Br 1992; 74:50.</a></li><li><a class="nounderline abstract_t">Fisher CG, Blachut PA, Salvian AJ, et al. Effectiveness of pneumatic leg compression devices for the prevention of thromboembolic disease in orthopaedic trauma patients: a prospective, randomized study of compression alone versus no prophylaxis. J Orthop Trauma 1995; 9:1.</a></li><li><a class="nounderline abstract_t">McKenna R, Galante J, Bachmann F, et al. Prevention of venous thromboembolism after total knee replacement by high-dose aspirin or intermittent calf and thigh compression. Br Med J 1980; 280:514.</a></li><li><a class="nounderline abstract_t">Hui AC, Heras-Palou C, Dunn I, et al. Graded compression stockings for prevention of deep-vein thrombosis after hip and knee replacement. J Bone Joint Surg Br 1996; 78:550.</a></li><li><a class="nounderline abstract_t">Pour AE, Keshavarzi NR, Purtill JJ, et al. Is venous foot pump effective in prevention of thromboembolic disease after joint arthroplasty: a meta-analysis. J Arthroplasty 2013; 28:410.</a></li><li><a class="nounderline abstract_t">Sakai T, Izumi M, Kumagai K, et al. Effects of a Foot Pump on the Incidence of Deep Vein Thrombosis After Total Knee Arthroplasty in Patients Given Edoxaban: A Randomized Controlled Study. Medicine (Baltimore) 2016; 95:e2247.</a></li><li><a class="nounderline abstract_t">Windisch C, Kolb W, Kolb K, et al. Pneumatic compression with foot pumps facilitates early postoperative mobilisation in total knee arthroplasty. Int Orthop 2011; 35:995.</a></li><li><a class="nounderline abstract_t">Fordyce MJ, Ling RS. A venous foot pump reduces thrombosis after total hip replacement. J Bone Joint Surg Br 1992; 74:45.</a></li><li><a class="nounderline abstract_t">Stranks GJ, MacKenzie NA, Grover ML, Fail T. The A-V Impulse System reduces deep-vein thrombosis and swelling after hemiarthroplasty for hip fracture. J Bone Joint Surg Br 1992; 74:775.</a></li><li><a class="nounderline abstract_t">Lachiewicz PF, Soileau ES. Mechanical calf compression and aspirin prophylaxis for total knee arthroplasty. Clin Orthop Relat Res 2007; 464:61.</a></li><li><a class="nounderline abstract_t">Comerota AJ, Katz ML, White JV. Why does prophylaxis with external pneumatic compression for deep vein thrombosis fail? Am J Surg 1992; 164:265.</a></li><li><a class="nounderline abstract_t">Cornwell EE 3rd, Chang D, Velmahos G, et al. Compliance with sequential compression device prophylaxis in at-risk trauma patients: a prospective analysis. Am Surg 2002; 68:470.</a></li><li><a class="nounderline abstract_t">Murakami M, McDill TL, Cindrick-Pounds L, et al. Deep venous thrombosis prophylaxis in trauma: improved compliance with a novel miniaturized pneumatic compression device. J Vasc Surg 2003; 38:923.</a></li></ol></div><div id="topicVersionRevision">Topic 1335 Version 53.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315265" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31794602" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315257" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35964704" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35964703" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Executive Summary: Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28734614" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Correlation of the Caprini Score and Venous Thromboembolism Incidence Following Primary Total Joint Arthroplasty-Results of a Single-Institution Protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16498018" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Frequency and timing of clinical venous thromboembolism after major joint surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22253396" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Symptomatic in-hospital deep vein thrombosis and pulmonary embolism following hip and knee arthroplasty among patients receiving recommended prophylaxis: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11114314" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Predictors of rehospitalization for symptomatic venous thromboembolism after total hip arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12958614" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20844157" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Risk factors for venous thromboembolism in patients undergoing total hip replacement and receiving routine thromboprophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15634263" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Epidemiology of venous thromboembolism in Asian patients undergoing major orthopedic surgery without thromboprophylaxis. The SMART study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12960538" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Risk factors for clinically relevant pulmonary embolism and deep venous thrombosis in patients undergoing primary hip or knee arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17908282" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Epidemiology of venous thromboembolism after lower limb arthroplasty: the FOTO study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19694660" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Early mobilization after total knee replacement reduces the incidence of deep venous thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23042665" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Mechanical and suboptimal pharmacologic prophylaxis and delayed mobilization but not morbid obesity are associated with venous thromboembolism after total knee arthroplasty: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20106897" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Reducing the risk of venous thromboembolism in patients admitted to hospital: summary of NICE guidance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15842354" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10904464" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin Trial Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11525697" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18582928" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17869635" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21175312" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Apixaban versus enoxaparin for thromboprophylaxis after hip replacement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29466159" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8684199" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8703168" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9031444" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Prolonged thromboprophylaxis following hip replacement surgery--results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9669750" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty--the Danish Prolonged Prophylaxis (DaPP) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11263636" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9679793" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11454370" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11712876" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22412039" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Prolonged versus standard-duration venous thromboprophylaxis in major orthopedic surgery: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23539696" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Extended venous thromboembolism prophylaxis in patients undergoing hip fracture surgery - the SAVE-HIP3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12796074" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Reduction of out-of-hospital symptomatic venous thromboembolism by extended thromboprophylaxis with low-molecular-weight heparin following elective hip arthroplasty: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27027384" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10836911" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18579811" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30453352" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Safety of In-Hospital Only Thromboprophylaxis after Fast-Track Total Hip and Knee Arthroplasty: A Prospective Follow-Up Study in 17,582 Procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27284271" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Clinical benefit of graduated compression stockings for prevention of venous thromboembolism after total knee arthroplasty: post hoc analysis of a phase 3 clinical study of edoxaban.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28159420" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Efficacy in Deep Vein Thrombosis Prevention With Extended Mechanical Compression Device Therapy and Prophylactic Aspirin Following Total Knee Arthroplasty: A Randomized Control Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28261425" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Intermittent Pneumatic Compression for the Prevention of Venous Thromboembolism after Total Hip Arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28261425" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Intermittent Pneumatic Compression for the Prevention of Venous Thromboembolism after Total Hip Arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28261425" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Intermittent Pneumatic Compression for the Prevention of Venous Thromboembolism after Total Hip Arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20568836" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Tinzaparin sodium: a review of its use in the prevention and treatment of deep vein thrombosis and pulmonary embolism, and in the prevention of clotting in the extracorporeal circuit during haemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20568836" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Tinzaparin sodium: a review of its use in the prevention and treatment of deep vein thrombosis and pulmonary embolism, and in the prevention of clotting in the extracorporeal circuit during haemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20568836" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Tinzaparin sodium: a review of its use in the prevention and treatment of deep vein thrombosis and pulmonary embolism, and in the prevention of clotting in the extracorporeal circuit during haemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18843459" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Prevention of postoperative venous thromboembolism in Japanese patients undergoing total hip or knee arthroplasty: two randomized, double-blind, placebo-controlled studies with three dosage regimens of enoxaparin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1321509" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Prevention of deep vein thrombosis after major knee surgery--a randomized, double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to placebo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8774203" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Ardeparin (low-molecular-weight heparin) vs graduated compression stockings for the prevention of venous thromboembolism. A randomized trial in patients undergoing knee surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3531851" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1314147" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The thromboprophylactic effect of a low-molecular-weight heparin (Fragmin) in hip fracture surgery. A placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28102615" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Comparative effectiveness of venous thromboembolism prophylaxis options for the patient undergoing total hip and knee replacement: a network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8413432" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8056798" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty. RD Heparin Arthroplasty Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8607589" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11407799" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8772214" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Subcutaneous low-molecular weight heparin or oral anticoagulants for the prevention of deep-vein thrombosis in elective hip and knee replacement? Fraxiparine Oral Anticoagulant Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15219187" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Prevention of venous thromboembolism in orthopedic surgery with vitamin K antagonists: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14668421" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9314399" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10428124" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12390061" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low-molecular-weight heparin with oral anticoagulant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10904465" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1848054" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3283548" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19438502" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Does acetyl salicylic acid (ASA) have a role in the prevention of venous thromboembolism?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7515115" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : A meta-analysis of methods to prevent venous thromboembolism following total hip replacement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16950076" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : VenaFlow plus Lovenox vs VenaFlow plus aspirin for thromboembolic disease prophylaxis in total knee arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25045166" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Aspirin versus anticoagulation for prevention of venous thromboembolism major lower extremity orthopedic surgery: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35997730" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Effect of Aspirin vs Enoxaparin on Symptomatic Venous Thromboembolism in Patients Undergoing Hip or Knee Arthroplasty: The CRISTAL Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18626046" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Low-molecular-weight heparin versus compression stockings for thromboprophylaxis after knee arthroscopy: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15274256" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Mechanical prophylaxis of deep-vein thrombosis after total hip replacement a randomised clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9049766" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : A comparison of intermittent calf compression and enoxaparin for thromboprophylaxis in total hip replacement. A pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9730125" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Comparison of the use of a foot pump with the use of low-molecular-weight heparin for the prevention of deep-vein thrombosis after total hip replacement. A prospective, randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10463739" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Prevention of deep-vein thrombosis after total knee replacement. Randomised comparison between a low-molecular-weight heparin (nadroparin) and mechanical prophylaxis with a foot-pump system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10463739" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Prevention of deep-vein thrombosis after total knee replacement. Randomised comparison between a low-molecular-weight heparin (nadroparin) and mechanical prophylaxis with a foot-pump system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10463739" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Prevention of deep-vein thrombosis after total knee replacement. Randomised comparison between a low-molecular-weight heparin (nadroparin) and mechanical prophylaxis with a foot-pump system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34259389" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22425218" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20923996" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22412038" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Oral direct Factor Xa inhibitors versus low-molecular-weight heparin to prevent venous thromboembolism in patients undergoing total hip or knee replacement: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Venous Thromboembolism Prophylaxis in Orthopedic Surgery [Internet]. Publication number 12-EHC020-EF.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22700784" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21198726" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Comparative Effectiveness of New Oral Anticoagulants and Standard Thromboprophylaxis in Patients Having Total Hip or Knee Replacement: A Systematic Review</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18579812" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19411100" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17116766" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16241946" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16409461" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21136019" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15333033" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15634273" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19132192" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17764540" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18534438" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25294589" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25653574" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : A randomized, open-label trial of edoxaban in Japanese patients with severe renal impairment undergoing lower-limb orthopedic surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25653574" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : A randomized, open-label trial of edoxaban in Japanese patients with severe renal impairment undergoing lower-limb orthopedic surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24154501" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Benefit-to-harm ratio of thromboprophylaxis for patients undergoing major orthopaedic surgery. A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26790579" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Effect of oral factor Xa inhibitor and low-molecular-weight heparin on surgical complications following total hip arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19657123" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Apixaban or enoxaparin for thromboprophylaxis after knee replacement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17868430" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20206776" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27980462" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Edoxaban versus enoxaparin for the prevention of venous thromboembolism after total knee or hip arthroplasty: pooled analysis of coagulation biomarkers and primary efficacy and safety endpoints from two phase 3 trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26716830" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29112548" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : European guidelines on perioperative venous thromboembolism prophylaxis: Aspirin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36652352" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23732713" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10776741" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28099298" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Low-Dose Aspirin Is Effective Chemoprophylaxis Against Clinically Important Venous Thromboembolism Following Total Joint Arthroplasty: A Preliminary Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31733981" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Low-Dose Aspirin Is Adequate for Venous Thromboembolism Prevention Following Total Joint Arthroplasty: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32011647" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Clinical Effectiveness and Safety of Aspirin for Venous Thromboembolism Prophylaxis After Total Hip and Knee Replacement: A Systematic Review and Meta-analysis of Randomized Clinical Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30347089" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Association of Aspirin With Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty Compared With Other Anticoagulants: A Noninferiority Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29292343" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Venous thromboembolic prophylaxis after simultaneous bilateral total knee arthroplasty: aspirin versus warfarin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30893231" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : The Use of Aspirin for Prophylaxis Against Venous Thromboembolism Decreases Mortality Following Primary Total Joint Arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35030114" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Aspirin Is an Effective Prophylaxis for Venous Thromboembolism in Ambulatory Patients with Femoral Neck Fracture Undergoing Hip Arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2650646" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : A randomized trial of less intense postoperative warfarin or aspirin therapy in the prevention of venous thromboembolism after surgery for fractured hip.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27265806" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Safety and Efficacy of High-Dose Unfractionated Heparin for Prevention of Venous Thromboembolism in Overweight and Obese Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24136071" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23522854" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Thromboembolic and bleeding outcomes of low-intensity warfarin thromboprophylaxis following elective total hip arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25555318" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Thromboembolic and bleeding outcomes of extended duration low-intensity warfarin following elective total knee arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21919556" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Warfarin prophylaxis in patients after total knee or hip arthroplasty--international normalized ratio patterns and venous thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/62111" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Warfarin sodium in prevention of deep venous thrombosis and pulmonary embolism in patients with fractured neck of femur.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1774568" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Prospective randomized trial of sequential compression devices vs low-dose warfarin for deep venous thrombosis prophylaxis in total hip arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1583760" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Comparison of warfarin and external pneumatic compression in prevention of venous thrombosis after total hip replacement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3572408" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Low-dose warfarin versus external pneumatic compression for prophylaxis against venous thromboembolism following total hip replacement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1864061" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Intermittent pneumatic compression versus coumadin. Prevention of deep vein thrombosis in lower-extremity total joint arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31479138" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Effect of Low-Intensity vs Standard-Intensity Warfarin Prophylaxis on Venous Thromboembolism or Death Among Patients Undergoing Hip or Knee Arthroplasty: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315264" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12049860" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11794149" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11794148" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27797404" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Pentasaccharides for the prevention of venous thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12049858" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12196081" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16446183" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Flexibility in administration of fondaparinux for prevention of symptomatic venous thromboembolism in orthopaedic surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22882706" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Efficacy and safety of rivaroxaban or fondaparinux thromboprophylaxis in major orthopedic surgery: findings from the ORTHO-TEP registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24100922" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Retrospective comparison of three thromboprophylaxis agents, edoxaban, fondaparinux, and enoxaparin, for preventing venous thromboembolism in total knee arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12796070" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18843686" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism in high-risk patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18843686" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism in high-risk patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2182917" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Effectiveness of intermittent pneumatic leg compression for preventing deep vein thrombosis after total hip replacement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1732265" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Thrombo-embolic prophylaxis in total knee replacement. Evaluation of the A-V Impulse System.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7714648" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Effectiveness of pneumatic leg compression devices for the prevention of thromboembolic disease in orthopaedic trauma patients: a prospective, randomized study of compression alone versus no prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6989432" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Prevention of venous thromboembolism after total knee replacement by high-dose aspirin or intermittent calf and thigh compression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8682818" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Graded compression stockings for prevention of deep-vein thrombosis after hip and knee replacement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23102505" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Is venous foot pump effective in prevention of thromboembolic disease after joint arthroplasty: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26735531" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Effects of a Foot Pump on the Incidence of Deep Vein Thrombosis After Total Knee Arthroplasty in Patients Given Edoxaban: A Randomized Controlled Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20652250" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Pneumatic compression with foot pumps facilitates early postoperative mobilisation in total knee arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1732264" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : A venous foot pump reduces thrombosis after total hip replacement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1527133" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : The A-V Impulse System reduces deep-vein thrombosis and swelling after hemiarthroplasty for hip fracture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17632417" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Mechanical calf compression and aspirin prophylaxis for total knee arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1415927" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Why does prophylaxis with external pneumatic compression for deep vein thrombosis fail?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12017149" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Compliance with sequential compression device prophylaxis in at-risk trauma patients: a prospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14603195" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Deep venous thrombosis prophylaxis in trauma: improved compliance with a novel miniaturized pneumatic compression device.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
